You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameMetoprolol
Accession NumberDB00264  (APRD00208)
TypeSmall Molecule
GroupsApproved, Investigational
DescriptionMetoprolol is a cardioselective β1-adrenergic blocking agent used for acute myocardial infarction (MI), heart failure, angina pectoris and mild to moderate hypertension. It may also be used for supraventricular and tachyarrhythmias and prophylaxis for migraine headaches. Metoprolol is structurally similar to bisoprolol, acebutolol and atenolol in that it has two substituents in the para position of the benzene ring. The β1-selectivity of these agents is thought to be due in part to the large substituents in the para position. At low doses, metoprolol selectively blocks cardiac β1-adrenergic receptors with little activity against β2-adrenergic receptors of the lungs and vascular smooth muscle. Receptor selectivity decreases with higher doses. Unlike propranolol and pindolol, metoprolol does not exhibit membrane-stabilizing or intrinsic sympathomimetic activity. Membrane-stabilizing effects are only observed at doses much higher than those needed for β-adrenergic blocking activity. Metoprolol possesses a single chiral centre and is administered as a racemic mixture.
Structure
Thumb
Synonyms
(RS)-Metoprolol
1-(isopropylamino)-3-[4-(2-methoxyethyl)phenoxy]propan-2-ol
DL-metoprolol
Metoprolol slow release
External Identifiers
  • CGP-2175
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Ava-metoprololTablet50 mgOralAvanstra Inc2011-10-112014-08-21Canada
Ava-metoprololTablet100 mgOralAvanstra Inc2011-10-112014-08-21Canada
Ava-metoprolol (type L)Tablet50 mgOralAvanstra Inc2011-10-112014-08-21Canada
Ava-metoprolol (type L)Tablet100 mgOralAvanstra Inc2011-10-112014-08-21Canada
Betaloc Durules Tab 200 mgTablet, extended release200 mgOralAstrazeneca Canada Inc1980-12-312009-12-15Canada
Betaloc IV Inj 1 mg/mlSolution1 mgIntravenousAstrazeneca Canada Inc1987-12-312016-05-12Canada
Betaloc Tab 100 mgTablet100 mgOralAstrazeneca Canada Inc1977-12-312009-12-15Canada
Betaloc Tab 50 mgTablet50 mgOralAstrazeneca Canada Inc1978-12-312009-12-15Canada
Co Metoprolol-L Tablets 100mgTablet100 mgOralCobalt Pharmaceuticals CompanyNot applicableNot applicableCanada
Co Metoprolol-L Tablets 50mgTablet50 mgOralCobalt Pharmaceuticals CompanyNot applicableNot applicableCanada
Dom-metoprolol-B - Tab 50mgTablet50 mgOralDominion Pharmacal1996-12-31Not applicableCanada
Dom-metoprolol-B Tab 100mgTablet100 mgOralDominion Pharmacal1996-12-31Not applicableCanada
Dom-metoprolol-LTablet50 mgOralDominion Pharmacal1999-10-20Not applicableCanada
Dom-metoprolol-LTablet100 mgOralDominion Pharmacal1999-10-29Not applicableCanada
Dom-metoprolol-LTablet25 mgOralDominion Pharmacal2004-05-27Not applicableCanada
Gen-metoprolol Tablets 100mgTablet100 mgOralGenpharm Ulc1998-06-192009-08-05Canada
Gen-metoprolol Tablets 50mgTablet50 mgOralGenpharm Ulc1998-06-192009-08-05Canada
Jamp-metoprolol-LTablet50 mgOralJamp Pharma Corporation2010-10-21Not applicableCanada
Jamp-metoprolol-LTablet100 mgOralJamp Pharma Corporation2010-10-21Not applicableCanada
Jamp-metoprolol-LTablet25 mgOralJamp Pharma Corporation2010-10-21Not applicableCanada
Lopresor 100mgTablet100 mgOralNovartis Pharmaceuticals Canada Inc1977-12-31Not applicableCanada
Lopresor 50mgTablet50 mgOralNovartis Pharmaceuticals Canada Inc1977-12-31Not applicableCanada
Lopresor Inj 1.0mg/mlLiquid1 mgIntravenousNovartis Pharmaceuticals Canada Inc1987-12-31Not applicableCanada
Lopresor SR 100mgTablet, extended release100 mgOralNovartis Pharmaceuticals Canada Inc1985-12-31Not applicableCanada
Lopresor SR 200 mgTablet, extended release200 mgOralNovartis Pharmaceuticals Canada Inc1983-12-31Not applicableCanada
LopressorInjection, solution5 mg/5mLIntravenousNovartis Pharmaceuticals Corporation1978-01-15Not applicableUs
LopressorTablet100 mg/1OralValidus Pharmaceuticals LLC2014-05-05Not applicableUs
LopressorTablet50 mg/1OralNovartis Pharmaceuticals Corporation1978-01-152016-08-31Us
LopressorTablet100 mg/1OralNovartis Pharmaceuticals Corporation1978-01-152016-09-30Us
LopressorTablet50 mg/1OralValidus Pharmaceuticals LLC2014-05-05Not applicableUs
MetoprololTablet50 mgOralSanis Health Inc2010-05-31Not applicableCanada
MetoprololTablet100 mgOralSanis Health Inc2010-05-31Not applicableCanada
Metoprolol - 25Tablet25 mgOralPro Doc Limitee2007-10-26Not applicableCanada
Metoprolol SRTablet, extended release200 mgOralPro Doc Limitee2010-10-15Not applicableCanada
Metoprolol SRTablet, extended release100 mgOralPro Doc Limitee2010-10-15Not applicableCanada
Metoprolol SuccinateTablet, extended release50 mg/1OralClinical Solutions Wholesale2007-08-02Not applicableUs
Metoprolol SuccinateTablet, extended release25 mg/1OralPar Pharmaceutical Inc.2006-11-21Not applicableUs
Metoprolol SuccinateTablet, extended release25 mg/1OralPar Pharmaceutical Inc.2006-11-21Not applicableUs
Metoprolol SuccinateTablet, extended release50 mg/1OralA S Medication Solutions2007-08-02Not applicableUs
Metoprolol SuccinateTablet, extended release50 mg/1OralPar Pharmaceutical Inc.2007-08-02Not applicableUs
Metoprolol SuccinateTablet, extended release100 mg/1OralREMEDYREPACK INC.2013-03-08Not applicableUs
Metoprolol SuccinateTablet, extended release50 mg/1OralA S Medication Solutions2007-08-02Not applicableUs
Metoprolol SuccinateTablet, extended release25 mg/1OralNcs Health Care Of Ky, Inc Dba Vangard Labs2006-11-21Not applicableUs
Metoprolol SuccinateTablet, extended release50 mg/1OralPar Pharmaceutical Inc.2007-08-02Not applicableUs
Metoprolol SuccinateTablet, extended release100 mg/1OralA S Medication Solutions2007-07-26Not applicableUs
Metoprolol SuccinateTablet, extended release25 mg/1OralPd Rx Pharmaceuticals, Inc.2011-07-21Not applicableUs
Metoprolol SuccinateTablet, extended release100 mg/1OralPar Pharmaceutical Inc.2007-07-26Not applicableUs
Metoprolol SuccinateTablet, extended release25 mg/1OralREMEDYREPACK INC.2013-03-08Not applicableUs
Metoprolol SuccinateTablet, extended release100 mg/1OralA S Medication Solutions2007-07-26Not applicableUs
Metoprolol SuccinateTablet, extended release50 mg/1OralNcs Health Care Of Ky, Inc Dba Vangard Labs2007-08-02Not applicableUs
Metoprolol SuccinateTablet, extended release100 mg/1OralPar Pharmaceutical Inc.2007-07-26Not applicableUs
Metoprolol SuccinateTablet, extended release50 mg/1OralPd Rx Pharmaceuticals, Inc.2011-07-21Not applicableUs
Metoprolol SuccinateTablet, extended release200 mg/1OralPar Pharmaceutical Inc.2007-07-262016-11-30Us
Metoprolol SuccinateTablet, extended release25 mg/1OralA S Medication Solutions2006-11-21Not applicableUs
Metoprolol SuccinateTablet, extended release100 mg/1OralA S Medication Solutions2007-07-262019-09-30Us
Metoprolol SuccinateTablet, extended release200 mg/1OralPar Pharmaceutical Inc.2007-07-26Not applicableUs
Metoprolol Tartrate Injection USPSolution1 mgIntravenousSterimax IncNot applicableNot applicableCanada
Metoprolol Tartrate Injection USPSolution1 mgIntravenousSandoz Canada Incorporated2005-07-20Not applicableCanada
Metoprolol Tartrate Injection, USPSolution1 mgIntravenousMylan Pharmaceuticals UlcNot applicableNot applicableCanada
Metoprolol-100 Tab 100mgTablet100 mgOralPro Doc Limitee1985-12-31Not applicableCanada
Metoprolol-50 Tab 50mgTablet50 mgOralPro Doc Limitee1985-12-31Not applicableCanada
Metoprolol-LTablet50 mgOralSivem Pharmaceuticals Ulc2015-07-09Not applicableCanada
Metoprolol-LTablet100 mgOralMeliapharm Inc2004-07-222014-06-25Canada
Metoprolol-LTablet100 mgOralSivem Pharmaceuticals Ulc2015-07-09Not applicableCanada
Metoprolol-LTablet25 mgOralSorres Pharma Inc2009-02-262014-06-20Canada
Metoprolol-LTablet25 mgOralMeliapharm Inc2004-07-222014-06-25Canada
Metoprolol-LTablet50 mgOralSorres Pharma Inc2009-02-262014-06-20Canada
Metoprolol-LTablet25 mgOralSivem Pharmaceuticals Ulc2015-07-09Not applicableCanada
Metoprolol-LTablet50 mgOralMeliapharm Inc2004-07-222014-06-25Canada
Metoprolol-LTablet100 mgOralSorres Pharma Inc2009-02-262014-06-20Canada
Mylan-metoprolol (type L)Tablet50 mgOralMylan Pharmaceuticals Ulc1995-12-31Not applicableCanada
Mylan-metoprolol (type L)Tablet100 mgOralMylan Pharmaceuticals Ulc1995-12-31Not applicableCanada
Mylan-metoprolol (type L)Tablet25 mgOralMylan Pharmaceuticals Ulc2007-11-15Not applicableCanada
Ntp-metoprololTablet100 mgOralTeva Canada LimitedNot applicableNot applicableCanada
Ntp-metoprololTablet50 mgOralTeva Canada LimitedNot applicableNot applicableCanada
Ntp-metoprololTablet100 mgOralTeva Canada LimitedNot applicableNot applicableCanada
Ntp-metoprololTablet50 mgOralTeva Canada LimitedNot applicableNot applicableCanada
Nu-metop Tab 100mgTablet100 mgOralNu Pharm Inc1990-12-312012-09-04Canada
Nu-metop Tab 50mgTablet50 mgOralNu Pharm Inc1990-12-312012-09-04Canada
Nu-metoprololTablet50 mgOralNu Pharm IncNot applicableNot applicableCanada
Nu-metoprololTablet100 mgOralNu Pharm IncNot applicableNot applicableCanada
Nu-metoprololTablet25 mgOralNu Pharm IncNot applicableNot applicableCanada
Nu-metoprolol (type L)Tablet50 mgOralNu Pharm IncNot applicableNot applicableCanada
Nu-metoprolol (type L)Tablet100 mgOralNu Pharm IncNot applicableNot applicableCanada
Nu-metoprolol SRTablet, extended release100 mgOralNu Pharm IncNot applicableNot applicableCanada
Nu-metoprolol SRTablet, extended release200 mgOralNu Pharm IncNot applicableNot applicableCanada
Pendo-metoprolol-LTablet25 mgOralPendopharm Division Of De Pharmascience IncNot applicableNot applicableCanada
Pendo-metoprolol-LTablet50 mgOralPendopharm Division Of De Pharmascience IncNot applicableNot applicableCanada
Penta-metoprolol TabletsTablet50 mgOralPentapharm Ltd.Not applicableNot applicableCanada
Penta-metoprolol TabletsTablet100 mgOralPentapharm Ltd.Not applicableNot applicableCanada
PMS-metoprolol-B Tablets - 100mgTablet100 mgOralPharmascience Inc1995-12-31Not applicableCanada
PMS-metoprolol-B Tablets - 50mgTablet50 mgOralPharmascience Inc1995-12-31Not applicableCanada
PMS-metoprolol-LTablet25 mgOralPharmascience Inc2004-03-19Not applicableCanada
PMS-metoprolol-LTablet50 mgOralPharmascience Inc1998-04-16Not applicableCanada
PMS-metoprolol-LTablet100 mgOralPharmascience Inc1998-04-16Not applicableCanada
PMS-metoprolol-L SRTablet, extended release100 mgOralPharmascience IncNot applicableNot applicableCanada
PMS-metoprolol-L SRTablet, extended release200 mgOralPharmascience IncNot applicableNot applicableCanada
Q-metoprolol (type L)Tablet100 mgOralQd Pharmaceuticals UlcNot applicableNot applicableCanada
Q-metoprolol (type L)Tablet25 mgOralQd Pharmaceuticals UlcNot applicableNot applicableCanada
Q-metoprolol (type L)Tablet50 mgOralQd Pharmaceuticals UlcNot applicableNot applicableCanada
Riva-metoprolol LTablet100 mgOralLaboratoire Riva Inc2008-09-10Not applicableCanada
Riva-metoprolol LTablet25 mgOralLaboratoire Riva Inc2008-09-10Not applicableCanada
Riva-metoprolol LTablet50 mgOralLaboratoire Riva Inc2008-09-10Not applicableCanada
Sandoz Metoprolol (type L)Tablet100 mgOralSandoz Canada Incorporated2003-08-122012-02-20Canada
Sandoz Metoprolol (type L)Tablet50 mgOralSandoz Canada Incorporated2010-07-16Not applicableCanada
Sandoz Metoprolol (type L)Tablet100 mgOralSandoz Canada Incorporated2010-07-16Not applicableCanada
Sandoz Metoprolol (type L)Tablet50 mgOralSandoz Canada Incorporated2003-08-122012-02-22Canada
Sandoz Metoprolol SRTablet, extended release100 mgOralSandoz Canada Incorporated2007-12-13Not applicableCanada
Sandoz Metoprolol SRTablet, extended release200 mgOralSandoz Canada Incorporated2007-12-13Not applicableCanada
Teva-metoprololTablet50 mgOralTeva Canada Limited1989-12-31Not applicableCanada
Teva-metoprololTablet50 mgOralTeva Canada Limited1986-12-31Not applicableCanada
Teva-metoprololTablet100 mgOralTeva Canada Limited1989-12-31Not applicableCanada
Teva-metoprololTablet25 mgOralTeva Canada Limited2012-02-15Not applicableCanada
Teva-metoprololTablet100 mgOralTeva Canada Limited1986-12-31Not applicableCanada
Toprol XLTablet, extended release25 mg/1OralAphena Pharma Solutions Tennessee, Llc2001-03-26Not applicableUs
Toprol XLTablet, extended release200 mg/1OralAstra Zeneca Pharmaceuticals Lp1992-02-01Not applicableUs
Toprol XLTablet, extended release50 mg/1OralLake Erie Medical DBA Quality Care Products LLC1992-02-01Not applicableUs
Toprol XLTablet, extended release50 mg/1Oralbryant ranch prepack1992-02-01Not applicableUs
Toprol XLTablet, extended release50 mg/1OralCardinal Health2010-05-10Not applicableUs
Toprol XLTablet, extended release25 mg/1Oralbryant ranch prepack2001-03-26Not applicableUs
Toprol XLTablet, extended release25 mg/1OralAstra Zeneca Pharmaceuticals Lp2001-03-26Not applicableUs
Toprol XLTablet, extended release25 mg/1OralCardinal Health2010-05-10Not applicableUs
Toprol XLTablet, extended release200 mg/1Oralbryant ranch prepack1992-02-01Not applicableUs
Toprol XLTablet, extended release50 mg/1OralAstra Zeneca Pharmaceuticals Lp1992-02-01Not applicableUs
Toprol XLTablet, extended release50 mg/1OralAphena Pharma Solutions Tennessee, Llc1992-02-01Not applicableUs
Toprol XLTablet, extended release100 mg/1OralCardinal Health2010-05-10Not applicableUs
Toprol XLTablet, extended release100 mg/1Oralbryant ranch prepack1992-02-01Not applicableUs
Toprol XLTablet, extended release100 mg/1OralAstra Zeneca Pharmaceuticals Lp1992-02-01Not applicableUs
Toprolxl XLTablet, extended release50 mg/1OralREMEDYREPACK INC.2013-03-08Not applicableUs
Toprolxl XLTablet, extended release25 mg/1OralREMEDYREPACK INC.2013-10-04Not applicableUs
Toprolxl XLTablet, extended release100 mg/1OralREMEDYREPACK INC.2013-10-04Not applicableUs
Approved Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Apo Metoprolol (type L) Tab 50mgTablet50 mgOralApotex Inc1988-12-31Not applicableCanada
Apo Metoprolol Tab 100mgTablet100 mgOralApotex Inc1984-12-31Not applicableCanada
Apo Metoprolol Tab 50mgTablet50 mgOralApotex Inc1984-12-31Not applicableCanada
Apo-metoprololTablet25 mgOralApotex Inc2002-10-08Not applicableCanada
Apo-metoprolol (type L) Tab 100mgTablet100 mgOralApotex Inc1988-12-31Not applicableCanada
Apo-metoprolol SRTablet, extended release100 mgOralApotex Inc2007-07-30Not applicableCanada
Apo-metoprolol SRTablet, extended release200 mgOralApotex Inc2007-07-30Not applicableCanada
MetoprololInjection5 mg/5mLIntravenousClaris Lifesciences Inc.2012-09-25Not applicableUs
MetoprololInjection, solution5 mg/5mLIntravenousFresenius Kabi USA, LLC2010-10-28Not applicableUs
MetoprololInjection, solution1 mg/mLIntravenousSagent Pharmaceuticals2010-05-10Not applicableUs
MetoprololInjection5 mg/5mLIntravenousCardinal Health2012-09-25Not applicableUs
Metoprolol SuccinateTablet, film coated, extended release50 mg/301OralNorthwind Pharmaceuticals2014-05-07Not applicableUs
Metoprolol SuccinateTablet, film coated, extended release25 mg/1OralPhysicians Total Care, Inc.2008-02-06Not applicableUs
Metoprolol SuccinateTablet, film coated, extended release50 mg/1OralCardinal Health2012-01-27Not applicableUs
Metoprolol SuccinateTablet, film coated, extended release25 mg/1OralA S Medication Solutions2009-08-04Not applicableUs
Metoprolol SuccinateTablet, film coated, extended release25 mg/1OralPreferred Pharmaceuticals Inc.2016-08-09Not applicableUs
Metoprolol SuccinateTablet, film coated, extended release100 mg/1OralMajor Pharmaceuticals2010-10-05Not applicableUs
Metoprolol SuccinateTablet, film coated, extended release25 mg/1OralMylan Pharmaceuticals Inc.2011-12-212017-06-30Us
Metoprolol SuccinateTablet, film coated, extended release25 mg/1Oralbryant ranch prepack2010-07-22Not applicableUs
Metoprolol SuccinateTablet, extended release25 mg/1OralBlue Point Laboratories2014-01-01Not applicableUs
Metoprolol SuccinateTablet, film coated, extended release25 mg/1OralInternational Labs, Inc.2011-09-222016-10-13Us
Metoprolol SuccinateTablet, film coated, extended release25 mg/1OralA S Medication Solutions2009-08-04Not applicableUs
Metoprolol SuccinateTablet, film coated, extended release100 mg/1OralActavis Pharma, Inc.2010-04-15Not applicableUs
Metoprolol SuccinateTablet, film coated, extended release100 mg/1OralProficient Rx LP2010-04-15Not applicableUs
Metoprolol SuccinateTablet, film coated, extended release200 mg/1OralWockhardt USA LLC.2010-07-22Not applicableUs
Metoprolol SuccinateTablet, extended release50 mg/1OralA S Medication Solutions2012-09-10Not applicableUs
Metoprolol SuccinateTablet, film coated, extended release50 mg/1OralMylan Institutional Inc.2012-01-27Not applicableUs
Metoprolol SuccinateTablet, film coated, extended release200 mg/1OralNcs Health Care Of Ky, Inc Dba Vangard Labs2010-07-22Not applicableUs
Metoprolol SuccinateTablet, extended release100 mg/1OralMc Kesson Packaging Services Business Unit Of Mc Kesson Corporation2011-02-02Not applicableUs
Metoprolol SuccinateTablet, extended release50 mg/1OralRebel Distributors Corp2009-08-03Not applicableUs
Metoprolol SuccinateTablet, film coated, extended release25 mg/1OralUnit Dose Services2010-07-22Not applicableUs
Metoprolol SuccinateTablet, extended release25 mg/1OralDr. Reddy's Laboratories Limited2012-09-10Not applicableUs
Metoprolol SuccinateTablet, film coated, extended release200 mg/1OralWockhardt Limited2010-07-22Not applicableUs
Metoprolol SuccinateTablet, extended release200 mg/1OralGolden State Medical Supply, Inc.2010-04-15Not applicableUs
Metoprolol SuccinateTablet, extended release50 mg/1OralAmerican Health Packaging2014-03-06Not applicableUs
Metoprolol SuccinateTablet, extended release50 mg/1OralCardinal Health2012-09-10Not applicableUs
Metoprolol SuccinateTablet, film coated, extended release50 mg/1OralCardinal Health2010-08-13Not applicableUs
Metoprolol SuccinateTablet, film coated, extended release50 mg/1OralPd Rx Pharmaceuticals, Inc.2009-08-04Not applicableUs
Metoprolol SuccinateTablet, film coated, extended release25 mg/301OralNorthwind Pharmaceuticals2014-05-06Not applicableUs
Metoprolol SuccinateTablet, film coated, extended release50 mg/1OralPhysicians Total Care, Inc.2007-08-03Not applicableUs
Metoprolol SuccinateTablet, film coated, extended release25 mg/1OralCardinal Health2012-01-27Not applicableUs
Metoprolol SuccinateTablet, film coated, extended release50 mg/1OralA S Medication Solutions2009-08-04Not applicableUs
Metoprolol SuccinateTablet, film coated, extended release25 mg/1OralWockhardt Limited2010-07-22Not applicableUs
Metoprolol SuccinateTablet, extended release25 mg/1OralMajor Pharmaceuticals2012-09-10Not applicableUs
Metoprolol SuccinateTablet, film coated, extended release50 mg/1OralMylan Pharmaceuticals Inc.2011-12-212017-06-30Us
Metoprolol SuccinateTablet, film coated, extended release25 mg/1OralClinical Solutions Wholesale2010-07-22Not applicableUs
Metoprolol SuccinateTablet, film coated, extended release25 mg/1OralNcs Health Care Of Ky, Inc Dba Vangard Labs2010-07-22Not applicableUs
Metoprolol SuccinateTablet, film coated, extended release100 mg/1OralSt Marys Medical Park Pharmacy2013-08-08Not applicableUs
Metoprolol SuccinateTablet, film coated, extended release50 mg/1Oralbryant ranch prepack2010-07-22Not applicableUs
Metoprolol SuccinateTablet, extended release25 mg/1OralAidarex Pharmaceuticals LLC2012-09-10Not applicableUs
Metoprolol SuccinateTablet, extended release50 mg/1OralBlue Point Laboratories2014-01-01Not applicableUs
Metoprolol SuccinateTablet, film coated, extended release50 mg/1OralInternational Labs, Inc.2011-09-222016-10-13Us
Metoprolol SuccinateTablet, extended release100 mg/1OralProficient Rx LP2012-09-10Not applicableUs
Metoprolol SuccinateTablet, extended release25 mg/1OralGolden State Medical Supply, Inc.2013-03-22Not applicableUs
Metoprolol SuccinateTablet, film coated, extended release200 mg/1OralActavis Pharma, Inc.2010-04-15Not applicableUs
Metoprolol SuccinateTablet, extended release100 mg/1OralREMEDYREPACK INC.2016-01-12Not applicableUs
Metoprolol SuccinateTablet, extended release100 mg/1OralLegacy Pharmaceutical Packaging, Llc2012-09-10Not applicableUs
Metoprolol SuccinateTablet, film coated, extended release100 mg/1OralMylan Institutional Inc.2012-01-27Not applicableUs
Metoprolol SuccinateTablet, extended release25 mg/1OralNcs Health Care Of Ky, Inc Dba Vangard Labs2012-09-10Not applicableUs
Metoprolol SuccinateTablet, film coated, extended release25 mg/1OralWockhardt USA LLC.2010-07-22Not applicableUs
Metoprolol SuccinateTablet, extended release100 mg/1OralRebel Distributors Corp2010-04-15Not applicableUs
Metoprolol SuccinateTablet, film coated, extended release25 mg/1OralREMEDYREPACK INC.2013-03-082016-04-05Us
Metoprolol SuccinateTablet, extended release50 mg/1OralDr. Reddy's Laboratories Limited2012-09-10Not applicableUs
Metoprolol SuccinateTablet, film coated, extended release25 mg/1OralMajor Pharmaceuticals2010-10-05Not applicableUs
Metoprolol SuccinateTablet, extended release50 mg/1OralPreferred Pharmaceuticals, Inc.2016-11-02Not applicableUs
Metoprolol SuccinateTablet, film coated, extended release50 mg/1OralLake Erie Medical DBA Quality Care Products LLC2010-07-22Not applicableUs
Metoprolol SuccinateTablet, extended release50 mg/1OralCarilion Materials Management2014-01-01Not applicableUs
Metoprolol SuccinateTablet, extended release100 mg/1Oralbryant ranch prepack2010-04-15Not applicableUs
Metoprolol SuccinateTablet, extended release50 mg/1OralMc Kesson Contract Packaging2012-09-10Not applicableUs
Metoprolol SuccinateTablet, film coated, extended release100 mg/1OralPhysicians Total Care, Inc.2010-01-05Not applicableUs
Metoprolol SuccinateTablet, extended release25 mg/1OralLegacy Pharmaceutical Packaging, Llc2012-09-10Not applicableUs
Metoprolol SuccinateTablet, film coated, extended release50 mg/1OralWockhardt Limited2010-07-22Not applicableUs
Metoprolol SuccinateTablet, extended release50 mg/1OralMajor Pharmaceuticals2012-09-10Not applicableUs
Metoprolol SuccinateTablet, film coated, extended release100 mg/1OralMylan Pharmaceuticals Inc.2011-12-212017-06-30Us
Metoprolol SuccinateTablet, film coated, extended release100 mg/1OralClinical Solutions Wholesale2010-07-22Not applicableUs
Metoprolol SuccinateTablet, film coated, extended release50 mg/1OralNcs Health Care Of Ky, Inc Dba Vangard Labs2010-07-22Not applicableUs
Metoprolol SuccinateTablet, extended release50 mg/1OralSt Marys Medical Park Pharmacy2013-08-08Not applicableUs
Metoprolol SuccinateTablet, extended release50 mg/1OralGolden State Medical Supply, Inc.2013-03-22Not applicableUs
Metoprolol SuccinateTablet, film coated, extended release100 mg/1OralInternational Labs, Inc.2011-09-222016-10-13Us
Metoprolol SuccinateTablet, film coated, extended release50 mg/1OralLake Erie Medical DBA Quality Care Products LLC2009-08-04Not applicableUs
Metoprolol SuccinateTablet, extended release50 mg/1OralCardinal Health2014-03-06Not applicableUs
Metoprolol SuccinateTablet, extended release100 mg/1OralDr. Reddy's Laboratories Limited2012-09-10Not applicableUs
Metoprolol SuccinateTablet, extended release100 mg/1OralA S Medication Solutions2012-09-10Not applicableUs
Metoprolol SuccinateTablet, extended release50 mg/1OralNcs Health Care Of Ky, Inc Dba Vangard Labs2012-09-10Not applicableUs
Metoprolol SuccinateTablet, film coated, extended release25 mg/1OralActavis Pharma, Inc.2009-08-04Not applicableUs
Metoprolol SuccinateTablet, film coated, extended release25 mg/1OralProficient Rx LP2009-08-04Not applicableUs
Metoprolol SuccinateTablet, film coated, extended release50 mg/1OralWockhardt USA LLC.2010-07-22Not applicableUs
Metoprolol SuccinateTablet, film coated, extended release50 mg/1OralAphena Pharma Solutions Tennessee, Llc2009-08-04Not applicableUs
Metoprolol SuccinateTablet, extended release100 mg/1OralBlue Point Laboratories2013-11-25Not applicableUs
Metoprolol SuccinateTablet, film coated, extended release100 mg/1OralREMEDYREPACK INC.2013-06-172016-04-05Us
Metoprolol SuccinateTablet, extended release100 mg/1OralAmerican Health Packaging2014-05-12Not applicableUs
Metoprolol SuccinateTablet, film coated, extended release50 mg/1OralCardinal Health2010-10-05Not applicableUs
Metoprolol SuccinateTablet, film coated, extended release50 mg/1OralMajor Pharmaceuticals2010-10-05Not applicableUs
Metoprolol SuccinateTablet, film coated, extended release100 mg/1OralUnit Dose Services2010-07-22Not applicableUs
Metoprolol SuccinateTablet, film coated, extended release25 mg/1OralLake Erie Medical DBA Quality Care Products LLC2009-08-04Not applicableUs
Metoprolol SuccinateTablet, extended release50 mg/1OralDispensing Solutions, Inc.2009-08-04Not applicableUs
Metoprolol SuccinateTablet, extended release25 mg/1OralPd Rx Pharmaceuticals, Inc.2012-09-10Not applicableUs
Metoprolol SuccinateTablet, film coated, extended release25 mg/1OralMylan Institutional Inc.2012-01-27Not applicableUs
Metoprolol SuccinateTablet, film coated, extended release100 mg/1OralNcs Health Care Of Ky, Inc Dba Vangard Labs2010-07-22Not applicableUs
Metoprolol SuccinateTablet, film coated, extended release25 mg/1OralSt Marys Medical Park Pharmacy2013-08-08Not applicableUs
Metoprolol SuccinateTablet, extended release50 mg/1OralREMEDYREPACK INC.2016-01-08Not applicableUs
Metoprolol SuccinateTablet, extended release50 mg/1OralUnit Dose Services2012-09-10Not applicableUs
Metoprolol SuccinateTablet, film coated, extended release200 mg/1OralPhysicians Total Care, Inc.2007-07-31Not applicableUs
Metoprolol SuccinateTablet, extended release50 mg/1OralLegacy Pharmaceutical Packaging, Llc2012-09-10Not applicableUs
Metoprolol SuccinateTablet, film coated, extended release100 mg/1OralWockhardt Limited2010-07-22Not applicableUs
Metoprolol SuccinateTablet, extended release100 mg/1OralMajor Pharmaceuticals2012-09-10Not applicableUs
Metoprolol SuccinateTablet, film coated, extended release200 mg/1OralMylan Pharmaceuticals Inc.2011-12-212017-06-30Us
Metoprolol SuccinateTablet, film coated, extended release100 mg/1OralPreferred Pharmaceuticals, Inc.2016-11-02Not applicableUs
Metoprolol SuccinateTablet, extended release50 mg/1OralMedsource Pharmaceuticals2012-09-10Not applicableUs
Metoprolol SuccinateTablet, extended release100 mg/1OralGolden State Medical Supply, Inc.2010-04-15Not applicableUs
Metoprolol SuccinateTablet, film coated, extended release100 mg/1OralLake Erie Medical DBA Quality Care Products LLC2010-07-22Not applicableUs
Metoprolol SuccinateTablet, extended release25 mg/1OralAmerican Health Packaging2014-03-06Not applicableUs
Metoprolol SuccinateTablet, extended release100 mg/1OralCardinal Health2014-05-12Not applicableUs
Metoprolol SuccinateTablet, film coated, extended release25 mg/1OralCardinal Health2010-08-13Not applicableUs
Metoprolol SuccinateTablet, extended release25 mg/1OralAphena Pharma Solutions Tennessee, Llc2013-03-22Not applicableUs
Metoprolol SuccinateTablet, extended release25 mg/1OralCardinal Health2014-03-06Not applicableUs
Metoprolol SuccinateTablet, extended release200 mg/1OralDr. Reddy's Laboratories Limited2012-09-10Not applicableUs
Metoprolol SuccinateTablet, film coated, extended release100 mg/1OralCardinal Health2010-08-13Not applicableUs
Metoprolol SuccinateTablet, extended release25 mg/1OralREMEDYREPACK INC.2016-05-19Not applicableUs
Metoprolol SuccinateTablet, extended release25 mg/1OralPreferred Pharmaceuticals, Inc.2016-11-16Not applicableUs
Metoprolol SuccinateTablet, extended release100 mg/1OralNcs Health Care Of Ky, Inc Dba Vangard Labs2012-09-10Not applicableUs
Metoprolol SuccinateTablet, film coated, extended release50 mg/1OralActavis Pharma, Inc.2009-08-04Not applicableUs
Metoprolol SuccinateTablet, film coated, extended release50 mg/1OralProficient Rx LP2009-08-04Not applicableUs
Metoprolol SuccinateTablet, film coated, extended release100 mg/1OralWockhardt USA LLC.2010-07-22Not applicableUs
Metoprolol SuccinateTablet, film coated, extended release100 mg/1OralAphena Pharma Solutions Tennessee, Llc2010-04-15Not applicableUs
Metoprolol SuccinateTablet, extended release200 mg/1OralBlue Point Laboratories2013-11-25Not applicableUs
Metoprolol SuccinateTablet, film coated, extended release25 mg/1OralAvera Mc Kennan Hospital2015-03-09Not applicableUs
Metoprolol Succinate E/rTablet, film coated, extended release50 mg/1OralDIRECT RX2015-01-01Not applicableUs
Metoprolol Succinate Extended-releaseTablet, film coated, extended release190 mg/1OralEthex Corporation2009-11-01Not applicableUs
Metoprolol Succinate Extended-releaseTablet, film coated, extended release90 mg/1OralEthex Corporation2009-11-01Not applicableUs
Metoprolol Succinate Extended-releaseTablet, film coated, extended release47.5 mg/1OralEthex Corporation2009-11-01Not applicableUs
Metoprolol Succinate Extended-releaseTablet, film coated, extended release23.75 mg/1OralEthex Corporation2009-11-01Not applicableUs
Metoprolol TartateTablet100 mg/1OralREMEDYREPACK INC.2011-08-012016-11-02Us
Metoprolol TartateTablet50 mg/1OralNorthwind Pharmaceuticals2014-06-02Not applicableUs
Metoprolol TartrateTablet, film coated25 mg/1OralCronus Pharma LLC2007-09-112016-01-05Us
Metoprolol TartrateTablet, film coated50 mg/1OralSTAT Rx USA LLC1994-05-27Not applicableUs
Metoprolol TartrateTablet, film coated25 mg/1OralAvera Mc Kennan Hospital2015-03-05Not applicableUs
Metoprolol TartrateInjection, solution1 mg/mLIntravenousGeneral Injectables & Vaccines, Inc2010-08-01Not applicableUs
Metoprolol TartrateInjection, solution5 mg/5mLIntravenousSandoz Inc2007-10-022017-05-31Us
Metoprolol TartrateTablet, film coated50 mg/1OralCarilion Materials Management2007-09-11Not applicableUs
Metoprolol TartrateTablet, film coated50 mg/1OralPd Rx Pharmaceuticals, Inc.1994-05-27Not applicableUs
Metoprolol TartrateTablet, film coated50 mg/1OralSafecor Health, LLC2014-09-30Not applicableUs
Metoprolol TartrateTablet25 mg/1OralClinical Solutions Wholesale1997-07-01Not applicableUs
Metoprolol TartrateTablet, film coated25 mg/1OralIngenus Pharmaceuticals, LLC2011-05-01Not applicableUs
Metoprolol TartrateTablet100 mg/1OralNcs Health Care Of Ky, Inc Dba Vangard Labs1997-07-01Not applicableUs
Metoprolol TartrateTablet100 mg/1OralSt Marys Medical Park Pharmacy2013-05-15Not applicableUs
Metoprolol TartrateTablet, film coated100 mg/1OralAmerican Health Packaging2010-07-26Not applicableUs
Metoprolol TartrateTablet50 mg/1OralContract Pharmacy Services Pa2011-01-25Not applicableUs
Metoprolol TartrateTablet25 mg/1OralDispensing Solutions, Inc.2004-01-15Not applicableUs
Metoprolol TartrateTablet, film coated25 mg/1OralMc Kesson Contract Packaging2011-10-06Not applicableUs
Metoprolol TartrateTablet, film coated50 mg/1OralBlenheim Pharmacal, Inc.2010-10-08Not applicableUs
Metoprolol TartrateTablet, film coated100 mg/1OralMylan Institutional Inc.1994-05-03Not applicableUs
Metoprolol TartrateTablet, film coated25 mg/1OralREMEDYREPACK INC.2013-05-07Not applicableUs
Metoprolol TartrateTablet, film coated50 mg/1OralREMEDYREPACK INC.2016-04-04Not applicableUs
Metoprolol TartrateTablet, film coated25 mg/1OralCardinal Health2011-01-14Not applicableUs
Metoprolol TartrateInjection, solution5 mg/5mLIntravenousCardinal Health2008-05-05Not applicableUs
Metoprolol TartrateTablet, film coated25 mg/1OralREMEDYREPACK INC.2016-03-21Not applicableUs
Metoprolol TartrateInjection, solution1 mg/mLIntravenousCardinal Health2010-02-11Not applicableUs
Metoprolol TartrateTablet, film coated50 mg/1OralSandoz Inc1994-03-25Not applicableUs
Metoprolol TartrateTablet100 mg/1OralDIRECT RX2014-01-01Not applicableUs
Metoprolol TartrateTablet, film coated25 mg/1OralAphena Pharma Solutions Tennessee, Llc2007-09-11Not applicableUs
Metoprolol TartrateTablet, film coated100 mg/1OralNu Care Pharmaceuticals, Inc.2007-09-11Not applicableUs
Metoprolol TartrateTablet100 mg/1OralSun Pharmaceutical Industries, Inc.1997-07-01Not applicableUs
Metoprolol TartrateTablet, film coated50 mg/1OralRubicon Research Private Limited2014-11-17Not applicableUs
Metoprolol TartrateTablet, film coated50 mg/1OralTeva Pharmaceuticals USA Inc1995-04-06Not applicableUs
Metoprolol TartrateTablet, film coated50 mg/1OralGreenstone LLC2007-09-112016-03-31Us
Metoprolol TartrateTablet, film coated100 mg/1OralAidarex Pharmaceuticals LLC1994-05-27Not applicableUs
Metoprolol TartrateTablet25 mg/1OralMajor Pharmaceuticals2014-03-14Not applicableUs
Metoprolol TartrateTablet50 mg/1OralDIRECT RX2014-01-01Not applicableUs
Metoprolol TartrateTablet, film coated50 mg/1OralREMEDYREPACK INC.2015-05-15Not applicableUs
Metoprolol TartrateTablet50 mg/1OralProficient Rx LP1997-07-01Not applicableUs
Metoprolol TartrateTablet, film coated50 mg/1OralPd Rx Pharmaceuticals, Inc.1994-05-27Not applicableUs
Metoprolol TartrateTablet, film coated100 mg/1OralAphena Pharma Solutions Tennessee, Llc2013-04-22Not applicableUs
Metoprolol TartrateTablet, film coated25 mg/1OralPreferred Pharmaceuticals, Inc.2013-04-01Not applicableUs
Metoprolol TartrateTablet, film coated50 mg/1OralProficient Rx LP2007-09-11Not applicableUs
Metoprolol TartrateTablet, film coated25 mg/1OralREMEDYREPACK INC.2013-03-20Not applicableUs
Metoprolol TartrateTablet, film coated50 mg/1OralState of Florida DOH Central Pharmacy2009-07-01Not applicableUs
Metoprolol TartrateTablet, film coated25 mg/1OralCardinal Health2010-06-09Not applicableUs
Metoprolol TartrateTablet25 mg/1OralPreferred Pharmaceuticals, Inc.2015-01-13Not applicableUs
Metoprolol TartrateTablet50 mg/1OralCardinal Health1997-07-01Not applicableUs
Metoprolol TartrateTablet, film coated50 mg/1OralA S Medication Solutions1995-04-06Not applicableUs
Metoprolol TartrateTablet50 mg/1OralA S Medication Solutions2015-06-29Not applicableUs
Metoprolol TartrateTablet50 mg/1OralCardinal Health2013-08-25Not applicableUs
Metoprolol TartrateTablet, film coated50 mg/1OralREMEDYREPACK INC.2016-06-28Not applicableUs
Metoprolol TartrateTablet, film coated25 mg/1OralMajor Pharmaceuticals2010-05-17Not applicableUs
Metoprolol TartrateTablet, film coated25 mg/1OralPreferred Pharmaceuticals, Inc.2016-11-02Not applicableUs
Metoprolol TartrateTablet25 mg/1OralAlembic Pharmaceuticals Limited2014-03-14Not applicableUs
Metoprolol TartrateTablet25 mg/1OralSun Pharmaceutical Industries, Inc.2004-01-15Not applicableUs
Metoprolol TartrateTablet25 mg/1OralLake Erie Medical & Surgical Supply DBA Quality Care Products LLC2004-01-15Not applicableUs
Metoprolol TartrateTablet, film coated50 mg/1OralActavis Pharma, Inc.1994-05-27Not applicableUs
Metoprolol TartrateTablet100 mg/1OralAlembic Pharmaceuticals Inc.2015-10-15Not applicableUs
Metoprolol TartrateTablet50 mg/1OralLake Erie Medical DBA Quality Care Products LLC1997-07-01Not applicableUs
Metoprolol TartrateTablet, film coated50 mg/1OralAurobindo Pharma Limited2007-09-11Not applicableUs
Metoprolol TartrateTablet100 mg/1OralCardinal Health1997-07-012015-12-29Us
Metoprolol TartrateTablet, film coated25 mg/1OralAurolife Pharma LLC2010-09-17Not applicableUs
Metoprolol TartrateTablet100 mg/1OralMed Health Pharma, LLC2011-01-15Not applicableUs
Metoprolol TartrateTablet, film coated25 mg/1OralLucid Pharma Llc2007-09-11Not applicableUs
Metoprolol TartrateTablet, film coated100 mg/1OralMylan Pharmaceuticals Inc.1993-12-23Not applicableUs
Metoprolol TartrateTablet, film coated100 mg/1OralPhysicians Total Care, Inc.1994-11-29Not applicableUs
Metoprolol TartrateTablet25 mg/1OralDIRECT RX2014-01-01Not applicableUs
Metoprolol TartrateTablet, film coated25 mg/1OralVensun Pharmaceuticals, Inc.2015-08-14Not applicableUs
Metoprolol TartrateTablet, film coated50 mg/1OralContract Pharmacy Services Pa2009-06-10Not applicableUs
Metoprolol TartrateTablet, film coated50 mg/1OralLegacy Pharmaceutical Packaging, Llc2007-09-11Not applicableUs
Metoprolol TartrateTablet, film coated50 mg/1OralCronus Pharma LLC2007-09-112016-01-05Us
Metoprolol TartrateTablet50 mg/1OralRebel Distributors Corp.1996-12-10Not applicableUs
Metoprolol TartrateTablet, film coated25 mg/1OralState of Florida DOH Central Pharmacy2009-07-01Not applicableUs
Metoprolol TartrateTablet25 mg/1OralCarilion Materials Management2014-03-14Not applicableUs
Metoprolol TartrateTablet, film coated25 mg/1OralUnit Dose Services2007-09-11Not applicableUs
Metoprolol TartrateTablet25 mg/1OralSafecor Health, LLC2014-09-30Not applicableUs
Metoprolol TartrateTablet, film coated50 mg/1OralIngenus Pharmaceuticals, LLC2011-05-01Not applicableUs
Metoprolol TartrateTablet25 mg/1OralProficient Rx LP2004-01-15Not applicableUs
Metoprolol TartrateTablet, film coated25 mg/1OralRanbaxy Pharmaceuticals Inc.2009-03-24Not applicableUs
Metoprolol TartrateTablet50 mg/1OralTYA Pharmaceuticals1997-07-01Not applicableUs
Metoprolol TartrateTablet50 mg/1OralMc Kesson Contract Packaging2011-10-04Not applicableUs
Metoprolol TartrateTablet, film coated25 mg/1OralBlenheim Pharmacal, Inc.2013-12-20Not applicableUs
Metoprolol TartrateTablet50 mg/1OralMed Health Pharma, LLC2011-01-15Not applicableUs
Metoprolol TartrateTablet50 mg/1OralREMEDYREPACK INC.2013-05-23Not applicableUs
Metoprolol TartrateTablet, film coated100 mg/1OralREMEDYREPACK INC.2016-04-08Not applicableUs
Metoprolol TartrateTablet, film coated100 mg/1OralCardinal Health2011-01-14Not applicableUs
Metoprolol TartrateTablet, film coated50 mg/1OralCardinal Health2009-06-10Not applicableUs
Metoprolol TartrateTablet, film coated50 mg/1OralNcs Health Care Of Ky, Inc Dba Vangard Labs1993-12-23Not applicableUs
Metoprolol TartrateTablet, film coated50 mg/1OralCardinal Health2013-04-22Not applicableUs
Metoprolol TartrateTablet, film coated25 mg/1OralA S Medication Solutions2007-09-11Not applicableUs
Metoprolol TartrateTablet, film coated100 mg/1OralSandoz Inc1994-03-25Not applicableUs
Metoprolol TartrateTablet, film coated100 mg/1OralA S Medication Solutions2007-09-11Not applicableUs
Metoprolol TartrateTablet, film coated50 mg/1OralAphena Pharma Solutions Tennessee, Llc2007-09-11Not applicableUs
Metoprolol TartrateTablet50 mg/1OralSun Pharmaceutical Industries, Inc.1997-07-01Not applicableUs
Metoprolol TartrateTablet, film coated100 mg/1OralRubicon Research Private Limited2014-11-17Not applicableUs
Metoprolol TartrateTablet, film coated100 mg/1OralTeva Pharmaceuticals USA Inc1995-04-06Not applicableUs
Metoprolol TartrateInjection, solution1 mg/mLIntravenousCardinal Health1998-07-06Not applicableUs
Metoprolol TartrateTablet, film coated100 mg/1OralA S Medication Solutions1993-12-23Not applicableUs
Metoprolol TartrateTablet, film coated25 mg/1OralCitron Pharma LLC2007-09-11Not applicableUs
Metoprolol TartrateTablet50 mg/1OralREMEDYREPACK INC.2011-07-072016-10-28Us
Metoprolol TartrateTablet50 mg/1OralMajor Pharmaceuticals2014-03-14Not applicableUs
Metoprolol TartrateTablet100 mg/1OralREMEDYREPACK INC.2011-11-02Not applicableUs
Metoprolol TartrateTablet, film coated100 mg/1OralProficient Rx LP2007-09-11Not applicableUs
Metoprolol TartrateTablet, film coated50 mg/1OralPd Rx Pharmaceuticals, Inc.2011-05-04Not applicableUs
Metoprolol TartrateTablet, film coated50 mg/1OralAphena Pharma Solutions Tennessee, Llc2013-04-22Not applicableUs
Metoprolol TartrateTablet100 mg/1OralPreferred Pharmaceuticals, Inc.2012-02-14Not applicableUs
Metoprolol TartrateTablet, film coated25 mg/1OralPd Rx Pharmaceuticals, Inc.2011-05-04Not applicableUs
Metoprolol TartrateTablet, film coated100 mg/1OralState of Florida DOH Central Pharmacy2014-11-01Not applicableUs
Metoprolol TartrateTablet, film coated50 mg/1OralCardinal Health2013-07-23Not applicableUs
Metoprolol TartrateInjection, solution1 mg/mLIntravenousAmerican Regent, Inc.2010-02-11Not applicableUs
Metoprolol TartrateTablet, film coated25 mg/1OralPhysicians Total Care, Inc.2004-03-15Not applicableUs
Metoprolol TartrateTablet, film coated25 mg/1OralProficient Rx LP2007-09-11Not applicableUs
Metoprolol TartrateInjection, solution1 mg/mLIntravenousCardinal Health1998-07-06Not applicableUs
Metoprolol TartrateTablet50 mg/1OralA S Medication Solutions2015-06-29Not applicableUs
Metoprolol TartrateInjection, solution5 mg/5mLIntravenousCardinal Health2007-05-30Not applicableUs
Metoprolol TartrateTablet, film coated50 mg/1OralREMEDYREPACK INC.2016-09-08Not applicableUs
Metoprolol TartrateTablet50 mg/1OralAlembic Pharmaceuticals Limited2014-03-14Not applicableUs
Metoprolol TartrateTablet100 mg/1OralClinical Solutions Wholesale1997-07-01Not applicableUs
Metoprolol TartrateTablet100 mg/1OralUnit Dose Services1997-07-01Not applicableUs
Metoprolol TartrateTablet, film coated100 mg/1OralActavis Pharma, Inc.1994-05-27Not applicableUs
Metoprolol TartrateTablet, film coated25 mg/1OralSt Marys Medical Park Pharmacy2014-04-21Not applicableUs
Metoprolol TartrateTablet, film coated25 mg/1OralAmerican Health Packaging2010-06-09Not applicableUs
Metoprolol TartrateTablet, film coated100 mg/1Oralbryant ranch prepack2009-03-15Not applicableUs
Metoprolol TartrateTablet, film coated100 mg/1OralAurobindo Pharma Limited2007-09-11Not applicableUs
Metoprolol TartrateTablet, film coated25 mg/1OralCardinal Health2010-01-122015-12-29Us
Metoprolol TartrateTablet, film coated50 mg/1OralAurolife Pharma LLC2010-09-17Not applicableUs
Metoprolol TartrateTablet100 mg/1OralCardinal Health2014-03-14Not applicableUs
Metoprolol TartrateTablet, film coated50 mg/1OralLucid Pharma Llc2007-09-11Not applicableUs
Metoprolol TartrateTablet50 mg/1OralProficient Rx LP2004-01-15Not applicableUs
Metoprolol TartrateTablet, film coated50 mg/1OralVensun Pharmaceuticals, Inc.2015-08-14Not applicableUs
Metoprolol TartrateTablet, film coated100 mg/1OralContract Pharmacy Services Pa2009-06-10Not applicableUs
Metoprolol TartrateTablet, film coated100 mg/1OralLegacy Pharmaceutical Packaging, Llc2007-09-11Not applicableUs
Metoprolol TartrateTablet, film coated100 mg/1OralCronus Pharma LLC2007-09-112016-01-05Us
Metoprolol TartrateTablet100 mg/1OralRebel Distributors Corp.1996-12-10Not applicableUs
Metoprolol TartrateTablet100 mg/1OralNorthwind Pharmaceuticals, LLC2014-09-12Not applicableUs
Metoprolol TartrateTablet25 mg/1OralState of Florida DOH Central Pharmacy2009-07-01Not applicableUs
Metoprolol TartrateTablet, film coated25 mg/1OralUnit Dose Services2009-03-24Not applicableUs
Metoprolol TartrateTablet, film coated25 mg/1OralA S Medication Solutions2004-02-23Not applicableUs
Metoprolol TartrateTablet, film coated100 mg/1OralA S Medication Solutions2007-09-11Not applicableUs
Metoprolol TartrateTablet, film coated50 mg/1OralREMEDYREPACK INC.2011-04-192016-10-13Us
Metoprolol TartrateTablet, film coated100 mg/1OralIngenus Pharmaceuticals, LLC2011-05-01Not applicableUs
Metoprolol TartrateInjection, solution5 mg/5mLIntravenousWest Ward Pharmaceuticals Corp2007-05-30Not applicableUs
Metoprolol TartrateTablet25 mg/1OralAlembic Pharmaceuticals Inc.2015-10-15Not applicableUs
Metoprolol TartrateTablet, film coated50 mg/1OralRanbaxy Pharmaceuticals Inc.2009-03-15Not applicableUs
Metoprolol TartrateTablet100 mg/1OralLake Erie Medical DBA Quality Care Products LLC1997-07-01Not applicableUs
Metoprolol TartrateTablet, film coated25 mg/1OralTYA Pharmaceuticals2009-03-24Not applicableUs
Metoprolol TartrateInjection5 mg/5mLIntravenousGland Pharma Limited2014-10-06Not applicableUs
Metoprolol TartrateTablet100 mg/1OralMc Kesson Contract Packaging2011-11-04Not applicableUs
Metoprolol TartrateTablet100 mg/1OralBlenheim Pharmacal, Inc.2013-10-21Not applicableUs
Metoprolol TartrateTablet50 mg/1OralMed Health Pharma, LLC2011-01-15Not applicableUs
Metoprolol TartrateTablet, film coated25 mg/1OralREMEDYREPACK INC.2014-02-20Not applicableUs
Metoprolol TartrateTablet, film coated25 mg/1OralMylan Pharmaceuticals Inc.2004-02-23Not applicableUs
Metoprolol TartrateTablet, film coated50 mg/1OralCardinal Health2011-01-14Not applicableUs
Metoprolol TartrateTablet, film coated100 mg/1OralCardinal Health2009-06-10Not applicableUs
Metoprolol TartrateTablet, film coated100 mg/1OralNcs Health Care Of Ky, Inc Dba Vangard Labs1993-12-23Not applicableUs
Metoprolol TartrateTablet, film coated25 mg/1OralCardinal Health2013-04-22Not applicableUs
Metoprolol TartrateTablet50 mg/1OralClinical Solutions Wholesale, Llc2015-06-29Not applicableUs
Metoprolol TartrateTablet, film coated50 mg/1OralMajor Pharmaceuticals2009-06-10Not applicableUs
Metoprolol TartrateTablet, film coated100 mg/1OralAphena Pharma Solutions Tennessee, Llc2007-09-11Not applicableUs
Metoprolol TartrateInjection, solution1 mg/mLIntravenousHospira, Inc.1993-12-21Not applicableUs
Metoprolol TartrateTablet100 mg/1OralSun Pharmaceutical Industries, Inc.1997-07-01Not applicableUs
Metoprolol TartrateTablet, film coated50 mg/1OralLake Erie Medical DBA Quality Care Products LLC2011-01-27Not applicableUs
Metoprolol TartrateTablet50 mg/1OralState of Florida DOH Central Pharmacy2014-01-01Not applicableUs
Metoprolol TartrateTablet, film coated37.5 mg/1OralMylan Pharmaceuticals Inc.2016-03-01Not applicableUs
Metoprolol TartrateInjection, solution1 mg/mLIntravenousCardinal Health2008-04-29Not applicableUs
Metoprolol TartrateTablet, film coated50 mg/1OralCitron Pharma LLC2007-09-11Not applicableUs
Metoprolol TartrateTablet, film coated50 mg/1OralA S Medication Solutions2007-09-11Not applicableUs
Metoprolol TartrateTablet100 mg/1OralMajor Pharmaceuticals2014-03-14Not applicableUs
Metoprolol TartrateTablet50 mg/1OralLake Erie Medical DBA Quality Care Products LLC2015-06-29Not applicableUs
Metoprolol TartrateTablet100 mg/1OralREMEDYREPACK INC.2011-12-01Not applicableUs
Metoprolol TartrateTablet, film coated25 mg/1OralMylan Institutional Inc.2004-09-20Not applicableUs
Metoprolol TartrateTablet50 mg/1OralPreferred Pharmaceuticals, Inc.2012-02-14Not applicableUs
Metoprolol TartrateTablet, film coated25 mg/1OralREMEDYREPACK INC.2013-03-192016-10-25Us
Metoprolol TartrateTablet, film coated50 mg/1OralA S Medication Solutions2007-09-11Not applicableUs
Metoprolol TartrateTablet50 mg/1OralNorthwind Pharmaceuticals, LLC2014-09-19Not applicableUs
Metoprolol TartrateTablet, film coated100 mg/1OralLucid Pharma Llc2007-09-11Not applicableUs
Metoprolol TartrateTablet, film coated25 mg/1OralNcs Health Care Of Ky, Inc Dba Vangard Labs2011-05-05Not applicableUs
Metoprolol TartrateInjection, solution5 mg/5mLIntravenousPhysicians Total Care, Inc.2006-12-11Not applicableUs
Metoprolol TartrateTablet100 mg/1OralA S Medication Solutions2015-06-29Not applicableUs
Metoprolol TartrateTablet, film coated100 mg/1OralPd Rx Pharmaceuticals, Inc.1994-05-27Not applicableUs
Metoprolol TartrateTablet, film coated50 mg/1OralPreferred Pharmaceuticals Inc.2016-08-16Not applicableUs
Metoprolol TartrateTablet, film coated50 mg/1OralNu Care Pharmaceuticals, Inc.2007-09-11Not applicableUs
Metoprolol TartrateTablet100 mg/1OralAlembic Pharmaceuticals Limited2014-03-14Not applicableUs
Metoprolol TartrateTablet50 mg/1OralClinical Solutions Wholesale1997-07-01Not applicableUs
Metoprolol TartrateTablet50 mg/1OralNcs Health Care Of Ky, Inc Dba Vangard Labs1997-07-01Not applicableUs
Metoprolol TartrateTablet50 mg/1OralSt Marys Medical Park Pharmacy2013-05-15Not applicableUs
Metoprolol TartrateTablet, film coated50 mg/1OralAmerican Health Packaging2010-06-22Not applicableUs
Metoprolol TartrateTablet, film coated50 mg/1Oralbryant ranch prepack2009-03-15Not applicableUs
Metoprolol TartrateTablet, film coated50 mg/1OralMed Vantx, Inc.1995-04-06Not applicableUs
Metoprolol TartrateTablet, film coated100 mg/1OralGreenstone LLC2007-09-112015-10-31Us
Metoprolol TartrateTablet, film coated100 mg/1OralAurolife Pharma LLC2010-09-17Not applicableUs
Metoprolol TartrateTablet100 mg/1OralProficient Rx LP1997-07-01Not applicableUs
Metoprolol TartrateTablet25 mg/1Oralbryant ranch prepack2004-01-15Not applicableUs
Metoprolol TartrateTablet, film coated100 mg/1OralVensun Pharmaceuticals, Inc.2015-08-14Not applicableUs
Metoprolol TartrateTablet, film coated25 mg/1OralAphena Pharma Solutions Tennessee, Llc2013-04-22Not applicableUs
Metoprolol TartrateTablet50 mg/1OralPreferred Pharmaceuticals Inc.1997-07-01Not applicableUs
Metoprolol TartrateTablet25 mg/1OralRebel Distributors Corp.2004-01-15Not applicableUs
Metoprolol TartrateTablet, film coated50 mg/1OralUnit Dose Services2009-03-15Not applicableUs
Metoprolol TartrateTablet, film coated25 mg/1OralREMEDYREPACK INC.2013-03-15Not applicableUs
Metoprolol TartrateTablet, film coated100 mg/1OralState of Florida DOH Central Pharmacy2009-07-01Not applicableUs
Metoprolol TartrateTablet25 mg/1OralCardinal Health2004-01-15Not applicableUs
Metoprolol TartrateTablet25 mg/1OralA S Medication Solutions2015-06-29Not applicableUs
Metoprolol TartrateTablet, film coated50 mg/1OralA S Medication Solutions2007-09-11Not applicableUs
Metoprolol TartrateTablet, film coated25 mg/1OralREMEDYREPACK INC.2011-04-192016-10-13Us
Metoprolol TartrateInjection, solution1 mg/mLIntravenousHospira, Inc.1998-07-06Not applicableUs
Metoprolol TartrateTablet50 mg/1OralSun Pharmaceutical Industries, Inc.1997-07-01Not applicableUs
Metoprolol TartrateTablet, film coated100 mg/1OralLake Erie Medical & Surgical Supply DBA Quality Care Products LLC2012-03-16Not applicableUs
Metoprolol TartrateInjection, solution5 mg/5mLIntravenousWest Ward Pharmaceuticals Corp2007-05-30Not applicableUs
Metoprolol TartrateTablet50 mg/1OralAlembic Pharmaceuticals Inc.2015-10-15Not applicableUs
Metoprolol TartrateTablet, film coated100 mg/1OralRanbaxy Pharmaceuticals Inc.2009-03-15Not applicableUs
Metoprolol TartrateTablet, film coated25 mg/1OralAurobindo Pharma Limited2007-09-11Not applicableUs
Metoprolol TartrateTablet50 mg/1OralCardinal Health1997-07-012015-12-29Us
Metoprolol TartrateTablet, film coated50 mg/1OralBlenheim Pharmacal, Inc.1994-05-27Not applicableUs
Metoprolol TartrateTablet100 mg/1OralMed Health Pharma, LLC2011-01-15Not applicableUs
Metoprolol TartrateTablet, film coated100 mg/1OralREMEDYREPACK INC.2014-04-24Not applicableUs
Metoprolol TartrateTablet, film coated50 mg/1OralMylan Pharmaceuticals Inc.1993-12-23Not applicableUs
Metoprolol TartrateTablet, film coated50 mg/1OralPhysicians Total Care, Inc.1994-01-05Not applicableUs
Metoprolol TartrateTablet25 mg/1OralCardinal Health2013-08-25Not applicableUs
Metoprolol TartrateTablet25 mg/1OralClinical Solutions Wholesale, Llc2015-06-29Not applicableUs
Metoprolol TartrateTablet, film coated100 mg/1OralMajor Pharmaceuticals2009-06-10Not applicableUs
Metoprolol TartrateTablet25 mg/1OralREMEDYREPACK INC.2013-05-07Not applicableUs
Metoprolol TartrateTablet25 mg/1OralState of Florida DOH Central Pharmacy2014-11-01Not applicableUs
Metoprolol TartrateTablet, film coated75 mg/1OralMylan Pharmaceuticals Inc.2016-03-01Not applicableUs
Metoprolol TartrateTablet, film coated100 mg/1OralCitron Pharma LLC2007-09-11Not applicableUs
Metoprolol TartrateTablet, film coated25 mg/1OralA S Medication Solutions2007-09-112016-10-28Us
Metoprolol TartrateTablet50 mg/1OralBlenheim Pharmacal, Inc.2013-07-10Not applicableUs
Metoprolol TartrateTablet, film coated25 mg/1OralRubicon Research Private Limited2014-11-17Not applicableUs
Metoprolol TartrateTablet, film coated25 mg/1OralNew Horizon Rx Group, LLC2013-08-25Not applicableUs
Metoprolol TartrateTablet, film coated50 mg/1OralMylan Institutional Inc.1994-05-03Not applicableUs
Metoprolol TartrateTablet, film coated50 mg/1OralREMEDYREPACK INC.2013-03-182016-11-15Us
Metoprolol TartrateTablet, film coated100 mg/1OralA S Medication Solutions2007-09-11Not applicableUs
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
CorvitolNot Available
MinaxNot Available
SelokeenNot Available
TOPROLNot Available
Toprol-XLNot Available
TOPROLXLNot Available
Brand mixtures
NameLabellerIngredients
DutoprolAstra Zeneca Lp
HypertensololPhysician Therapeutics Llc
Lopressor HctValidus Pharmaceuticals LLC
Metoprolol Succinate and HydrochlorothiazideSolubiomix
Metoprolol Tartrate and HydrochlorothiazidePhysicians Total Care, Inc.
Metoprolol Tartrate and Hydrochlorothiazide 100 Mg-25 mgNorth Star Rx Llc
Metoprolol Tartrate and Hydrochlorothiazide 100 Mg-50 mgNorth Star Rx Llc
Metoprolol Tartrate and Hydrochlorothiazide 50 Mg-25 mgNorth Star Rx Llc
Salts
Name/CASStructureProperties
Metoprolol fumarate
119637-66-0
Thumb
  • InChI Key: BRIPGNJWPCKDQZ-WXXKFALUSA-N
  • Monoisotopic Mass: 650.377845947
  • Average Mass: 650.81
DBSALT001329
Metoprolol succinate
98418-47-4
Thumb
  • InChI Key: RGHAZVBIOOEVQX-UHFFFAOYSA-N
  • Monoisotopic Mass: 652.393496011
  • Average Mass: 652.826
DBSALT000863
Metoprolol tartrate
56392-17-7
Thumb
  • InChI Key: YGULWPYYGQCFMP-CEAXSRTFSA-N
  • Monoisotopic Mass: 684.383325251
  • Average Mass: 684.824
DBSALT000862
Categories
UNIIGEB06NHM23
CAS number51384-51-1
WeightAverage: 267.3639
Monoisotopic: 267.183443671
Chemical FormulaC15H25NO3
InChI KeyIUBSYMUCCVWXPE-UHFFFAOYSA-N
InChI
InChI=1S/C15H25NO3/c1-12(2)16-10-14(17)11-19-15-6-4-13(5-7-15)8-9-18-3/h4-7,12,14,16-17H,8-11H2,1-3H3
IUPAC Name
1-[4-(2-methoxyethyl)phenoxy]-3-[(propan-2-yl)amino]propan-2-ol
SMILES
COCCC1=CC=C(OCC(O)CNC(C)C)C=C1
Pharmacology
IndicationFor the management of acute myocardial infarction, angina pectoris, heart failure and mild to moderate hypertension. May be used to treat supraventricular and tachyarrhythmias and as prophylaxis for migraine headaches.
Structured Indications
PharmacodynamicsMetoprolol, a competitive, beta1-selective (cardioselective) adrenergic antagonist, is similar to atenolol in its moderate lipid solubility, lack of intrinsic sympathomimetic activity (ISA), and weak membrane stabilizing activity (MSA).
Mechanism of actionMetoprolol competes with adrenergic neurotransmitters such as catecholamines for binding at beta(1)-adrenergic receptors in the heart. Beta(1)-receptor blockade results in a decrease in heart rate, cardiac output, and blood pressure.
TargetKindPharmacological actionActionsOrganismUniProt ID
Beta-1 adrenergic receptorProteinyes
antagonist
HumanP08588 details
Beta-2 adrenergic receptorProteinunknown
antagonist
HumanP07550 details
Related Articles
AbsorptionRapid and complete, 50%
Volume of distributionNot Available
Protein binding12%
Metabolism

Primarily hepatic

SubstrateEnzymesProduct
Metoprolol
alpha-HydroxymetoprololDetails
Route of eliminationLess than 5% of an oral dose of metoprolol is recovered unchanged in the urine; the rest is excreted by the kidneys as metabolites that appear to have no beta-blocking activity.
Half life3-7 hours
ClearanceNot Available
ToxicityLD50=5500 mg/kg (orally in rats), toxic effects include bradycardia, hypotension, bronchospasm, and cardiac failure. LD50=2090 mg/kg (orally in mice)
Affected organisms
  • Humans and other mammals
Pathways
PathwayCategorySMPDB ID
Metoprolol Action PathwayDrug actionSMP00302
SNP Mediated Effects
Interacting Gene/EnzymeSNP RS IDAllele nameDefining changeEffectReference(s)
Beta-1 adrenergic receptor
Gene symbol: ADRB1
UniProt: P08588
rs1801253 Not AvailableC AlleleImproved response to blood pressure medication12844134
Beta-1 adrenergic receptor
Gene symbol: ADRB1
UniProt: P08588
rs1801252 Not AvailableA AlleleImproved response to blood pressure medication12844134
Beta-1 adrenergic receptor
Gene symbol: ADRB1
UniProt: P08588
rs1801253 Not AvailableG > CBetter response to drug therapy12844134
SNP Mediated Adverse Drug Reactions
Interacting Gene/EnzymeSNP RS IDAllele nameDefining changeAdverse ReactionReference(s)
Cytochrome P450 2D6
Gene symbol: CYP2D6
UniProt: P10635
rs3892097 CYP2D6*4A alleleIncreased risk of slow heart rate (bradycardia)18784654
Interactions
Drug Interactions
DrugInteractionDrug group
1,10-Phenanthroline1,10-Phenanthroline may increase the bradycardic activities of Metoprolol.Experimental
4-Methoxyamphetamine4-Methoxyamphetamine may increase the atrioventricular blocking (AV block) activities of Metoprolol.Experimental, Illicit
7,8-DICHLORO-1,2,3,4-TETRAHYDROISOQUINOLINE7,8-DICHLORO-1,2,3,4-TETRAHYDROISOQUINOLINE may increase the hypotensive activities of Metoprolol.Experimental
AbirateroneThe serum concentration of Metoprolol can be increased when it is combined with Abiraterone.Approved
AcebutololThe serum concentration of Metoprolol can be increased when it is combined with Acebutolol.Approved
AceclofenacAceclofenac may decrease the antihypertensive activities of Metoprolol.Approved
AcepromazineAcepromazine may increase the hypotensive activities of Metoprolol.Approved, Vet Approved
AceprometazineAceprometazine may increase the hypotensive activities of Metoprolol.Approved
AcetaminophenThe serum concentration of Metoprolol can be increased when it is combined with Acetaminophen.Approved
AcetazolamideThe risk or severity of adverse effects can be increased when Metoprolol is combined with Acetazolamide.Approved, Vet Approved
AcetohexamideMetoprolol may increase the hypoglycemic activities of Acetohexamide.Withdrawn
AcetovanilloneAcetovanillone may decrease the antihypertensive activities of Metoprolol.Investigational
AcetylcholineThe metabolism of Acetylcholine can be decreased when combined with Metoprolol.Approved
AcetyldigitoxinMetoprolol may increase the bradycardic activities of Acetyldigitoxin.Approved
Acetylsalicylic acidThe serum concentration of Acetylsalicylic acid can be increased when it is combined with Metoprolol.Approved, Vet Approved
AdapaleneAdapalene may decrease the antihypertensive activities of Metoprolol.Approved
AfatinibThe serum concentration of Afatinib can be increased when it is combined with Metoprolol.Approved
AgmatineAgmatine may increase the atrioventricular blocking (AV block) activities of Metoprolol.Experimental, Investigational
AjmalineThe serum concentration of Metoprolol can be increased when it is combined with Ajmaline.Approved
AlbendazoleThe serum concentration of Metoprolol can be increased when it is combined with Albendazole.Approved, Vet Approved
AldesleukinThe risk or severity of adverse effects can be increased when Aldesleukin is combined with Metoprolol.Approved
AldosteroneThe serum concentration of Metoprolol can be decreased when it is combined with Aldosterone.Experimental
AlectinibThe serum concentration of Metoprolol can be increased when it is combined with Alectinib.Approved
AlfentanilThe serum concentration of Metoprolol can be increased when it is combined with Alfentanil.Approved, Illicit
AlfuzosinAlfuzosin may increase the hypotensive activities of Metoprolol.Approved, Investigational
AlimemazineAlimemazine may increase the hypotensive activities of Metoprolol.Approved, Vet Approved
AliskirenThe risk or severity of adverse effects can be increased when Metoprolol is combined with Aliskiren.Approved, Investigational
AlitretinoinThe serum concentration of Alitretinoin can be increased when it is combined with Metoprolol.Approved, Investigational
AlmotriptanThe metabolism of Almotriptan can be decreased when combined with Metoprolol.Approved, Investigational
AlogliptinThe metabolism of Alogliptin can be decreased when combined with Metoprolol.Approved
AlprenololThe metabolism of Alprenolol can be decreased when combined with Metoprolol.Approved, Withdrawn
AmantadineThe serum concentration of Metoprolol can be increased when it is combined with Amantadine.Approved
AmbenoniumAmbenonium may increase the bradycardic activities of Metoprolol.Approved
AmbrisentanThe serum concentration of Ambrisentan can be increased when it is combined with Metoprolol.Approved, Investigational
Ambroxol acefyllinateMetoprolol may decrease the bronchodilatory activities of Ambroxol acefyllinate.Experimental
AmifostineMetoprolol may increase the hypotensive activities of Amifostine.Approved, Investigational
AmilorideThe risk or severity of adverse effects can be increased when Metoprolol is combined with Amiloride.Approved
Aminohippuric acidThe serum concentration of Metoprolol can be increased when it is combined with Aminohippuric acid.Approved
AminophenazoneThe metabolism of Aminophenazone can be decreased when combined with Metoprolol.Approved, Withdrawn
AminophyllineMetoprolol may decrease the bronchodilatory activities of Aminophylline.Approved
AmiodaroneThe serum concentration of Metoprolol can be increased when it is combined with Amiodarone.Approved, Investigational
AmitriptylineThe serum concentration of Metoprolol can be increased when it is combined with Amitriptyline.Approved
AmlodipineThe serum concentration of Metoprolol can be increased when it is combined with Amlodipine.Approved
AmobarbitalAmobarbital may increase the hypotensive activities of Metoprolol.Approved, Illicit
AmodiaquineThe serum concentration of Metoprolol can be increased when it is combined with Amodiaquine.Approved
AmoxapineThe metabolism of Amoxapine can be decreased when combined with Metoprolol.Approved
AmphetamineThe serum concentration of Metoprolol can be increased when it is combined with Amphetamine.Approved, Illicit
Amphotericin BThe risk or severity of adverse effects can be increased when Metoprolol is combined with Amphotericin B.Approved, Investigational
AmprenavirThe serum concentration of Metoprolol can be decreased when it is combined with Amprenavir.Approved
AmsacrineThe serum concentration of Metoprolol can be increased when it is combined with Amsacrine.Approved
Amyl NitriteThe risk or severity of adverse effects can be increased when Metoprolol is combined with Amyl Nitrite.Approved
AnisodamineAnisodamine may decrease the antihypertensive activities of Metoprolol.Investigational
AntipyrineThe serum concentration of Metoprolol can be increased when it is combined with Antipyrine.Approved
AnvirzelMetoprolol may increase the bradycardic activities of Anvirzel.Investigational
ApixabanThe serum concentration of Apixaban can be increased when it is combined with Metoprolol.Approved
ApomorphineApomorphine may increase the atrioventricular blocking (AV block) activities of Metoprolol.Approved, Investigational
ApraclonidineThe risk or severity of adverse effects can be increased when Metoprolol is combined with Apraclonidine.Approved
ApremilastApremilast may decrease the antihypertensive activities of Metoprolol.Approved, Investigational
AprindineThe metabolism of Aprindine can be decreased when combined with Metoprolol.Approved
ArbutamineMetoprolol may decrease the bronchodilatory activities of Arbutamine.Approved
ArecolineThe risk or severity of adverse effects can be increased when Metoprolol is combined with Arecoline.Experimental
ArformoterolThe metabolism of Arformoterol can be decreased when combined with Metoprolol.Approved, Investigational
AripiprazoleThe serum concentration of Metoprolol can be increased when it is combined with Aripiprazole.Approved, Investigational
ArmodafinilThe metabolism of Metoprolol can be decreased when combined with Armodafinil.Approved, Investigational
ArotinololThe risk or severity of adverse effects can be increased when Metoprolol is combined with Arotinolol.Approved
Arsenic trioxideThe serum concentration of Arsenic trioxide can be increased when it is combined with Metoprolol.Approved, Investigational
ArtemetherThe metabolism of Artemether can be decreased when combined with Metoprolol.Approved
AsenapineThe serum concentration of Metoprolol can be increased when it is combined with Asenapine.Approved
AstemizoleThe serum concentration of Metoprolol can be increased when it is combined with Astemizole.Approved, Withdrawn
AtazanavirThe serum concentration of Atazanavir can be increased when it is combined with Metoprolol.Approved, Investigational
AtenololThe risk or severity of adverse effects can be increased when Metoprolol is combined with Atenolol.Approved
AtomoxetineThe serum concentration of Metoprolol can be increased when it is combined with Atomoxetine.Approved
AtorvastatinThe serum concentration of Metoprolol can be increased when it is combined with Atorvastatin.Approved
AxitinibThe serum concentration of Axitinib can be increased when it is combined with Metoprolol.Approved, Investigational
AzapropazoneAzapropazone may decrease the antihypertensive activities of Metoprolol.Withdrawn
AzelastineThe serum concentration of Metoprolol can be increased when it is combined with Azelastine.Approved
Azilsartan medoxomilThe risk or severity of adverse effects can be increased when Metoprolol is combined with Azilsartan medoxomil.Approved
AzithromycinThe serum concentration of Metoprolol can be increased when it is combined with Azithromycin.Approved
BalsalazideBalsalazide may decrease the antihypertensive activities of Metoprolol.Approved, Investigational
BambuterolMetoprolol may decrease the bronchodilatory activities of Bambuterol.Approved
BarbexacloneBarbexaclone may increase the hypotensive activities of Metoprolol.Experimental
BarbitalBarbital may increase the hypotensive activities of Metoprolol.Illicit
BarnidipineThe risk or severity of adverse effects can be increased when Metoprolol is combined with Barnidipine.Approved
BenazeprilThe risk or severity of adverse effects can be increased when Metoprolol is combined with Benazepril.Approved, Investigational
BendroflumethiazideThe risk or severity of adverse effects can be increased when Metoprolol is combined with Bendroflumethiazide.Approved
BenmoxinBenmoxin may increase the hypotensive activities of Metoprolol.Withdrawn
BenoxaprofenBenoxaprofen may decrease the antihypertensive activities of Metoprolol.Withdrawn
BenzatropineThe metabolism of Benzatropine can be decreased when combined with Metoprolol.Approved
BenzocaineThe serum concentration of Metoprolol can be increased when it is combined with Benzocaine.Approved
BenzphetamineBenzphetamine may increase the atrioventricular blocking (AV block) activities of Metoprolol.Approved, Illicit
Benzyl alcoholThe metabolism of Benzyl alcohol can be decreased when combined with Metoprolol.Approved
BepridilThe serum concentration of Metoprolol can be increased when it is combined with Bepridil.Approved, Withdrawn
BeractantMetoprolol may increase the bradycardic activities of Beractant.Approved
BetamethasoneThe serum concentration of Betamethasone can be increased when it is combined with Metoprolol.Approved, Vet Approved
BetaxololThe serum concentration of Metoprolol can be increased when it is combined with Betaxolol.Approved
BethanecholThe risk or severity of adverse effects can be increased when Metoprolol is combined with Bethanechol.Approved
BethanidineBethanidine may increase the atrioventricular blocking (AV block) activities of Metoprolol.Approved
Betulinic AcidBetulinic Acid may decrease the antihypertensive activities of Metoprolol.Investigational
BicalutamideThe serum concentration of Metoprolol can be increased when it is combined with Bicalutamide.Approved
BimatoprostMetoprolol may increase the hypotensive activities of Bimatoprost.Approved, Investigational
BiperidenThe serum concentration of Metoprolol can be increased when it is combined with Biperiden.Approved
BisoprololThe risk or severity of adverse effects can be increased when Metoprolol is combined with Bisoprolol.Approved
BL-1020BL-1020 may increase the hypotensive activities of Metoprolol.Investigational
BoceprevirThe serum concentration of Boceprevir can be increased when it is combined with Metoprolol.Approved
BortezomibThe serum concentration of Metoprolol can be increased when it is combined with Bortezomib.Approved, Investigational
BosentanMetoprolol may increase the hypotensive activities of Bosentan.Approved, Investigational
BosutinibThe serum concentration of Bosutinib can be increased when it is combined with Metoprolol.Approved
Brentuximab vedotinThe serum concentration of Brentuximab vedotin can be increased when it is combined with Metoprolol.Approved
BretyliumBretylium may increase the bradycardic activities of Metoprolol.Approved
BrexpiprazoleThe serum concentration of Brexpiprazole can be increased when it is combined with Metoprolol.Approved
BrimonidineBrimonidine may increase the atrioventricular blocking (AV block) activities of Metoprolol.Approved
BrimonidineBrimonidine may increase the antihypertensive activities of Metoprolol.Approved
BromfenacBromfenac may decrease the antihypertensive activities of Metoprolol.Approved
BromocriptineBromocriptine may increase the atrioventricular blocking (AV block) activities of Metoprolol.Approved, Investigational
BrompheniramineThe serum concentration of Metoprolol can be increased when it is combined with Brompheniramine.Approved
BucillamineBucillamine may decrease the antihypertensive activities of Metoprolol.Investigational
BucindololMetoprolol may increase the orthostatic hypotensive activities of Bucindolol.Investigational
BufuralolThe metabolism of Bufuralol can be decreased when combined with Metoprolol.Experimental, Investigational
BumetanideThe risk or severity of adverse effects can be increased when Metoprolol is combined with Bumetanide.Approved
BupivacaineThe serum concentration of Bupivacaine can be increased when it is combined with Metoprolol.Approved, Investigational
BupranololMetoprolol may increase the hypotensive activities of Bupranolol.Approved
BuprenorphineThe serum concentration of Metoprolol can be increased when it is combined with Buprenorphine.Approved, Illicit, Investigational, Vet Approved
BupropionThe serum concentration of Metoprolol can be increased when it is combined with Bupropion.Approved
BuspironeThe serum concentration of Metoprolol can be increased when it is combined with Buspirone.Approved, Investigational
CabazitaxelThe serum concentration of Cabazitaxel can be increased when it is combined with Metoprolol.Approved
CabergolineMetoprolol may increase the vasoconstricting activities of Cabergoline.Approved
CaffeineThe serum concentration of Caffeine can be increased when it is combined with Metoprolol.Approved
CalfactantMetoprolol may increase the bradycardic activities of Calfactant.Approved
CamptothecinThe serum concentration of Camptothecin can be increased when it is combined with Metoprolol.Experimental
CanagliflozinThe risk or severity of adverse effects can be increased when Metoprolol is combined with Canagliflozin.Approved
CandesartanThe risk or severity of adverse effects can be increased when Metoprolol is combined with Candesartan.Approved
CandoxatrilMetoprolol may increase the hypotensive activities of Candoxatril.Experimental
CaptoprilThe risk or severity of adverse effects can be increased when Metoprolol is combined with Captopril.Approved
CarbacholThe risk or severity of adverse effects can be increased when Metoprolol is combined with Carbachol.Approved
CarbamazepineThe metabolism of Metoprolol can be increased when combined with Carbamazepine.Approved, Investigational
CarbetocinThe risk or severity of adverse effects can be increased when Metoprolol is combined with Carbetocin.Approved
CarbinoxamineThe serum concentration of Metoprolol can be increased when it is combined with Carbinoxamine.Approved
CarfilzomibThe serum concentration of Carfilzomib can be increased when it is combined with Metoprolol.Approved
CariprazineThe metabolism of Cariprazine can be decreased when combined with Metoprolol.Approved
CaroxazoneCaroxazone may increase the hypotensive activities of Metoprolol.Withdrawn
CarprofenCarprofen may decrease the antihypertensive activities of Metoprolol.Approved, Vet Approved, Withdrawn
CarteololThe serum concentration of Metoprolol can be increased when it is combined with Carteolol.Approved
CarvedilolMetoprolol may increase the orthostatic hypotensive activities of Carvedilol.Approved, Investigational
CaspofunginThe serum concentration of Metoprolol can be increased when it is combined with Caspofungin.Approved
CastanospermineCastanospermine may decrease the antihypertensive activities of Metoprolol.Experimental
CelecoxibThe serum concentration of Metoprolol can be increased when it is combined with Celecoxib.Approved, Investigational
CeliprololMetoprolol may decrease the bronchodilatory activities of Celiprolol.Approved, Investigational
CephalexinThe metabolism of Cephalexin can be decreased when combined with Metoprolol.Approved, Vet Approved
CeritinibMetoprolol may increase the bradycardic activities of Ceritinib.Approved
CerivastatinThe serum concentration of Metoprolol can be increased when it is combined with Cerivastatin.Withdrawn
CevimelineThe metabolism of Cevimeline can be decreased when combined with Metoprolol.Approved
ChloramphenicolThe metabolism of Metoprolol can be decreased when combined with Chloramphenicol.Approved, Vet Approved
ChlordiazepoxideThe metabolism of Chlordiazepoxide can be decreased when combined with Metoprolol.Approved, Illicit
ChloroquineThe serum concentration of Metoprolol can be increased when it is combined with Chloroquine.Approved, Vet Approved
ChlorothiazideThe risk or severity of adverse effects can be increased when Metoprolol is combined with Chlorothiazide.Approved, Vet Approved
ChlorphenamineThe serum concentration of Metoprolol can be increased when it is combined with Chlorphenamine.Approved
ChlorpromazineThe serum concentration of Metoprolol can be increased when it is combined with Chlorpromazine.Approved, Vet Approved
ChlorpropamideThe serum concentration of Metoprolol can be increased when it is combined with Chlorpropamide.Approved
ChlorprothixeneThe serum concentration of Metoprolol can be increased when it is combined with Chlorprothixene.Approved, Withdrawn
ChlorthalidoneThe risk or severity of adverse effects can be increased when Metoprolol is combined with Chlorthalidone.Approved
ChlorzoxazoneThe metabolism of Chlorzoxazone can be decreased when combined with Metoprolol.Approved
CholecalciferolThe serum concentration of Metoprolol can be increased when it is combined with Cholecalciferol.Approved, Nutraceutical
CholesterolThe serum concentration of Metoprolol can be increased when it is combined with Cholesterol.Experimental
Cholic AcidThe serum concentration of Metoprolol can be decreased when it is combined with Cholic Acid.Approved
CilazaprilThe risk or severity of adverse effects can be increased when Metoprolol is combined with Cilazapril.Approved
CilnidipineThe risk or severity of adverse effects can be increased when Metoprolol is combined with Cilnidipine.Approved
CilostazolThe metabolism of Cilostazol can be decreased when combined with Metoprolol.Approved
CimetidineThe serum concentration of Metoprolol can be increased when it is combined with Cimetidine.Approved
CinacalcetThe serum concentration of Metoprolol can be increased when it is combined with Cinacalcet.Approved
CinnarizineThe metabolism of Cinnarizine can be decreased when combined with Metoprolol.Approved
CiprofloxacinThe serum concentration of Metoprolol can be increased when it is combined with Ciprofloxacin.Approved, Investigational
CisaprideThe serum concentration of Metoprolol can be increased when it is combined with Cisapride.Approved, Investigational, Withdrawn
CisplatinThe serum concentration of Cisplatin can be increased when it is combined with Metoprolol.Approved
CitalopramThe serum concentration of Metoprolol can be increased when it is combined with Citalopram.Approved
ClarithromycinThe serum concentration of Metoprolol can be increased when it is combined with Clarithromycin.Approved
ClemastineThe serum concentration of Metoprolol can be increased when it is combined with Clemastine.Approved
ClenbuterolMetoprolol may decrease the bronchodilatory activities of Clenbuterol.Approved, Vet Approved
ClevidipineThe risk or severity of adverse effects can be increased when Metoprolol is combined with Clevidipine.Approved
ClobazamThe serum concentration of Metoprolol can be increased when it is combined with Clobazam.Approved, Illicit
ClofarabineThe risk or severity of adverse effects can be increased when Metoprolol is combined with Clofarabine.Approved, Investigational
ClofazimineThe serum concentration of Metoprolol can be increased when it is combined with Clofazimine.Approved, Investigational
ClomifeneThe serum concentration of Clomifene can be increased when it is combined with Metoprolol.Approved, Investigational
ClomipramineThe serum concentration of Metoprolol can be increased when it is combined with Clomipramine.Approved, Vet Approved
ClonidineClonidine may increase the atrioventricular blocking (AV block) activities of Metoprolol.Approved
ClonixinClonixin may decrease the antihypertensive activities of Metoprolol.Approved
ClopidogrelThe serum concentration of Clopidogrel can be increased when it is combined with Metoprolol.Approved, Nutraceutical
ClotrimazoleThe serum concentration of Metoprolol can be increased when it is combined with Clotrimazole.Approved, Vet Approved
ClozapineThe serum concentration of Metoprolol can be increased when it is combined with Clozapine.Approved
CobicistatThe serum concentration of Metoprolol can be increased when it is combined with Cobicistat.Approved
CobimetinibThe serum concentration of Cobimetinib can be increased when it is combined with Metoprolol.Approved
CocaineThe serum concentration of Metoprolol can be increased when it is combined with Cocaine.Approved, Illicit
CodeineThe serum concentration of Metoprolol can be increased when it is combined with Codeine.Approved, Illicit
ColchicineThe serum concentration of Colchicine can be increased when it is combined with Metoprolol.Approved
ColforsinThe serum concentration of Metoprolol can be increased when it is combined with Colforsin.Experimental
ConivaptanThe risk or severity of adverse effects can be increased when Metoprolol is combined with Conivaptan.Approved, Investigational
Conjugated Equine EstrogensThe serum concentration of Conjugated Equine Estrogens can be increased when it is combined with Metoprolol.Approved
CoumaphosCoumaphos may increase the bradycardic activities of Metoprolol.Vet Approved
CrizotinibThe serum concentration of Crizotinib can be increased when it is combined with Metoprolol.Approved
CryptenamineMetoprolol may increase the hypotensive activities of Cryptenamine.Approved
CurcuminCurcumin may decrease the antihypertensive activities of Metoprolol.Investigational
CyclobenzaprineThe metabolism of Cyclobenzaprine can be decreased when combined with Metoprolol.Approved
CyclophosphamideThe serum concentration of Metoprolol can be increased when it is combined with Cyclophosphamide.Approved, Investigational
CyclosporineThe serum concentration of Metoprolol can be increased when it is combined with Cyclosporine.Approved, Investigational, Vet Approved
CyclothiazideMetoprolol may increase the hypotensive activities of Cyclothiazide.Approved
D-LimoneneD-Limonene may decrease the antihypertensive activities of Metoprolol.Investigational
Dabigatran etexilateThe serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Metoprolol.Approved
DabrafenibThe serum concentration of Metoprolol can be decreased when it is combined with Dabrafenib.Approved
DaclatasvirThe serum concentration of Metoprolol can be increased when it is combined with Daclatasvir.Approved
DactinomycinThe serum concentration of Metoprolol can be increased when it is combined with Dactinomycin.Approved
DapagliflozinThe risk or severity of adverse effects can be increased when Metoprolol is combined with Dapagliflozin.Approved
DapoxetineThe serum concentration of Metoprolol can be increased when it is combined with Dapoxetine.Investigational
DarifenacinThe serum concentration of Metoprolol can be increased when it is combined with Darifenacin.Approved, Investigational
DarunavirThe serum concentration of Metoprolol can be increased when it is combined with Darunavir.Approved
DasabuvirThe metabolism of Dasabuvir can be decreased when combined with Metoprolol.Approved
DasatinibThe serum concentration of Dasatinib can be increased when it is combined with Metoprolol.Approved, Investigational
DaunorubicinThe serum concentration of Metoprolol can be decreased when it is combined with Daunorubicin.Approved
DebrisoquinThe serum concentration of Debrisoquin can be increased when it is combined with Metoprolol.Approved
DecamethoniumDecamethonium may increase the bradycardic activities of Metoprolol.Approved
DelavirdineThe serum concentration of Metoprolol can be increased when it is combined with Delavirdine.Approved
DemecariumDemecarium may increase the bradycardic activities of Metoprolol.Approved
DeserpidineMetoprolol may increase the hypotensive activities of Deserpidine.Approved
DesfluraneThe risk or severity of adverse effects can be increased when Metoprolol is combined with Desflurane.Approved
DesipramineThe serum concentration of Metoprolol can be increased when it is combined with Desipramine.Approved
DeslanosideMetoprolol may increase the bradycardic activities of Deslanoside.Approved
DesloratadineThe serum concentration of Metoprolol can be increased when it is combined with Desloratadine.Approved, Investigational
DesvenlafaxineThe serum concentration of Metoprolol can be increased when it is combined with Desvenlafaxine.Approved
DexamethasoneThe serum concentration of Metoprolol can be decreased when it is combined with Dexamethasone.Approved, Investigational, Vet Approved
DexfenfluramineThe serum concentration of Metoprolol can be increased when it is combined with Dexfenfluramine.Approved, Illicit, Withdrawn
DexmedetomidineThe serum concentration of Metoprolol can be increased when it is combined with Dexmedetomidine.Approved, Vet Approved
DexmethylphenidateThe serum concentration of Metoprolol can be increased when it is combined with Dexmethylphenidate.Approved
DextroamphetamineThe serum concentration of Metoprolol can be increased when it is combined with Dextroamphetamine.Approved, Illicit
DextromethorphanThe serum concentration of Metoprolol can be increased when it is combined with Dextromethorphan.Approved
DextropropoxypheneThe serum concentration of Metoprolol can be increased when it is combined with Dextropropoxyphene.Approved, Illicit, Withdrawn
DiazepamThe serum concentration of Diazepam can be increased when it is combined with Metoprolol.Approved, Illicit, Vet Approved
DiazoxideDiazoxide may increase the hypotensive activities of Metoprolol.Approved
DichlorvosDichlorvos may increase the bradycardic activities of Metoprolol.Vet Approved
DiclofenacThe serum concentration of Metoprolol can be increased when it is combined with Diclofenac.Approved, Vet Approved
DiclofenamideThe risk or severity of adverse effects can be increased when Metoprolol is combined with Diclofenamide.Approved
DiethylstilbestrolThe serum concentration of Diethylstilbestrol can be increased when it is combined with Metoprolol.Approved
DiflunisalDiflunisal may decrease the antihypertensive activities of Metoprolol.Approved
DigitoxinThe serum concentration of Digitoxin can be increased when it is combined with Metoprolol.Approved
DigoxinThe serum concentration of Metoprolol can be decreased when it is combined with Digoxin.Approved
DihydralazineMetoprolol may increase the hypotensive activities of Dihydralazine.Investigational
DihydrocodeineThe metabolism of Dihydrocodeine can be decreased when combined with Metoprolol.Approved, Illicit
DihydroergotamineDihydroergotamine may increase the atrioventricular blocking (AV block) activities of Metoprolol.Approved
DihydrotestosteroneThe serum concentration of Dihydrotestosterone can be increased when it is combined with Metoprolol.Illicit
DiltiazemThe serum concentration of Metoprolol can be increased when it is combined with Diltiazem.Approved
Dimethyl sulfoxideThe serum concentration of Metoprolol can be increased when it is combined with Dimethyl sulfoxide.Approved, Vet Approved
DinutuximabThe risk or severity of adverse effects can be increased when Metoprolol is combined with Dinutuximab.Approved
DiphenhydramineThe serum concentration of Metoprolol can be increased when it is combined with Diphenhydramine.Approved
DipivefrinDipivefrin may increase the atrioventricular blocking (AV block) activities of Metoprolol.Approved
DipyridamoleDipyridamole may increase the bradycardic activities of Metoprolol.Approved
DisopyramideDisopyramide may increase the bradycardic activities of Metoprolol.Approved
DobutamineMetoprolol may decrease the bronchodilatory activities of Dobutamine.Approved
DocetaxelThe serum concentration of Docetaxel can be increased when it is combined with Metoprolol.Approved, Investigational
DolasetronThe metabolism of Dolasetron can be decreased when combined with Metoprolol.Approved
DomperidoneThe serum concentration of Domperidone can be increased when it is combined with Metoprolol.Approved, Investigational, Vet Approved
DonepezilDonepezil may increase the bradycardic activities of Metoprolol.Approved
DopamineThe metabolism of Dopamine can be decreased when combined with Metoprolol.Approved
DorzolamideMetoprolol may increase the hypotensive activities of Dorzolamide.Approved
DoxazosinMetoprolol may increase the orthostatic hypotensive activities of Doxazosin.Approved
DoxepinThe serum concentration of Metoprolol can be increased when it is combined with Doxepin.Approved
DoxorubicinThe serum concentration of Metoprolol can be increased when it is combined with Doxorubicin.Approved, Investigational
DronabinolThe serum concentration of Metoprolol can be increased when it is combined with Dronabinol.Approved, Illicit
DronedaroneThe serum concentration of Metoprolol can be increased when it is combined with Dronedarone.Approved
DroxicamDroxicam may decrease the antihypertensive activities of Metoprolol.Approved
DroxidopaDroxidopa may increase the atrioventricular blocking (AV block) activities of Metoprolol.Approved, Investigational
DuloxetineThe serum concentration of Metoprolol can be increased when it is combined with Duloxetine.Approved
DuvelisibDuvelisib may decrease the antihypertensive activities of Metoprolol.Investigational
DyphyllineMetoprolol may decrease the bronchodilatory activities of Dyphylline.Approved
E6201E6201 may decrease the antihypertensive activities of Metoprolol.Investigational
EbselenEbselen may decrease the antihypertensive activities of Metoprolol.Investigational
EchothiophateEchothiophate may increase the bradycardic activities of Metoprolol.Approved
EdoxabanThe serum concentration of Edoxaban can be increased when it is combined with Metoprolol.Approved
EdrophoniumEdrophonium may increase the bradycardic activities of Metoprolol.Approved
EfavirenzThe serum concentration of Metoprolol can be increased when it is combined with Efavirenz.Approved, Investigational
EfonidipineMetoprolol may increase the hypotensive activities of Efonidipine.Approved
ElbasvirThe serum concentration of Metoprolol can be increased when it is combined with Elbasvir.Approved
EletriptanThe serum concentration of Eletriptan can be increased when it is combined with Metoprolol.Approved, Investigational
EliglustatThe serum concentration of Eliglustat can be increased when it is combined with Metoprolol.Approved
EmpagliflozinThe risk or severity of adverse effects can be increased when Metoprolol is combined with Empagliflozin.Approved
EnalaprilThe risk or severity of adverse effects can be increased when Metoprolol is combined with Enalapril.Approved, Vet Approved
EnalaprilatMetoprolol may increase the hypotensive activities of Enalaprilat.Approved
EncainideThe metabolism of Encainide can be decreased when combined with Metoprolol.Approved, Withdrawn
EnclomipheneThe metabolism of Enclomiphene can be decreased when combined with Metoprolol.Investigational
EnzalutamideThe serum concentration of Metoprolol can be increased when it is combined with Enzalutamide.Approved
EphedraEphedra may increase the atrioventricular blocking (AV block) activities of Metoprolol.Approved, Nutraceutical, Withdrawn
EPIBATIDINEThe risk or severity of adverse effects can be increased when Metoprolol is combined with EPIBATIDINE.Experimental
EpinastineThe serum concentration of Metoprolol can be increased when it is combined with Epinastine.Approved, Investigational
EpinephrineEpinephrine may increase the atrioventricular blocking (AV block) activities of Metoprolol.Approved, Vet Approved
EpirizoleEpirizole may decrease the antihypertensive activities of Metoprolol.Approved
EplerenoneThe risk or severity of adverse effects can be increased when Metoprolol is combined with Eplerenone.Approved
EpoprostenolMetoprolol may increase the hypotensive activities of Epoprostenol.Approved
EprosartanThe risk or severity of adverse effects can be increased when Metoprolol is combined with Eprosartan.Approved
Ergoloid mesylateMetoprolol may increase the vasoconstricting activities of Ergoloid mesylate.Approved
ErgonovineMetoprolol may increase the vasoconstricting activities of Ergonovine.Approved
ErgotamineErgotamine may increase the atrioventricular blocking (AV block) activities of Metoprolol.Approved
ErlotinibThe serum concentration of Erlotinib can be increased when it is combined with Metoprolol.Approved, Investigational
ErythromycinThe serum concentration of Metoprolol can be decreased when it is combined with Erythromycin.Approved, Vet Approved
EscitalopramThe serum concentration of Metoprolol can be increased when it is combined with Escitalopram.Approved, Investigational
Eslicarbazepine acetateThe metabolism of Metoprolol can be decreased when combined with Eslicarbazepine acetate.Approved
EsmirtazapineThe metabolism of Esmirtazapine can be decreased when combined with Metoprolol.Investigational
EsmololThe risk or severity of adverse effects can be increased when Esmolol is combined with Metoprolol.Approved
EsomeprazoleThe metabolism of Metoprolol can be decreased when combined with Esomeprazole.Approved, Investigational
EstradiolThe serum concentration of Estradiol can be increased when it is combined with Metoprolol.Approved, Investigational, Vet Approved
EstramustineThe serum concentration of Metoprolol can be increased when it is combined with Estramustine.Approved
EstriolThe serum concentration of Metoprolol can be decreased when it is combined with Estriol.Approved, Vet Approved
EstroneThe serum concentration of Metoprolol can be decreased when it is combined with Estrone.Approved
Etacrynic acidThe risk or severity of adverse effects can be increased when Metoprolol is combined with Etacrynic acid.Approved
EtanerceptEtanercept may decrease the antihypertensive activities of Metoprolol.Approved, Investigational
Ethinyl EstradiolThe serum concentration of Ethinyl Estradiol can be increased when it is combined with Metoprolol.Approved
EthylmorphineThe metabolism of Ethylmorphine can be decreased when combined with Metoprolol.Approved, Illicit
EtodolacEtodolac may decrease the antihypertensive activities of Metoprolol.Approved, Investigational, Vet Approved
EtofenamateEtofenamate may decrease the antihypertensive activities of Metoprolol.Approved
EtomidateEtomidate may increase the atrioventricular blocking (AV block) activities of Metoprolol.Approved
EtoperidoneThe serum concentration of Metoprolol can be increased when it is combined with Etoperidone.Approved
EtoposideThe serum concentration of Metoprolol can be increased when it is combined with Etoposide.Approved
EtoricoxibThe serum concentration of Metoprolol can be increased when it is combined with Etoricoxib.Approved, Investigational
EtravirineThe serum concentration of Metoprolol can be increased when it is combined with Etravirine.Approved
Evening primrose oilEvening primrose oil may decrease the antihypertensive activities of Metoprolol.Approved
EverolimusThe serum concentration of Everolimus can be increased when it is combined with Metoprolol.Approved
exisulindexisulind may decrease the antihypertensive activities of Metoprolol.Investigational
EzetimibeThe serum concentration of Ezetimibe can be increased when it is combined with Metoprolol.Approved
FelodipineThe serum concentration of Metoprolol can be increased when it is combined with Felodipine.Approved, Investigational
FenbufenFenbufen may decrease the antihypertensive activities of Metoprolol.Approved
FenfluramineThe serum concentration of Metoprolol can be increased when it is combined with Fenfluramine.Illicit, Withdrawn
FenoldopamMetoprolol may increase the hypotensive activities of Fenoldopam.Approved
FenoprofenFenoprofen may decrease the antihypertensive activities of Metoprolol.Approved
FenoterolMetoprolol may decrease the bronchodilatory activities of Fenoterol.Approved
FentanylThe serum concentration of Metoprolol can be increased when it is combined with Fentanyl.Approved, Illicit, Investigational, Vet Approved
FenthionFenthion may increase the bradycardic activities of Metoprolol.Vet Approved
FesoterodineThe serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Metoprolol.Approved
FexofenadineThe serum concentration of Metoprolol can be increased when it is combined with Fexofenadine.Approved
FidaxomicinThe serum concentration of Fidaxomicin can be increased when it is combined with Metoprolol.Approved
FimasartanThe risk or severity of adverse effects can be increased when Metoprolol is combined with Fimasartan.Approved
FingolimodMetoprolol may increase the bradycardic activities of Fingolimod.Approved, Investigational
FlecainideThe serum concentration of Metoprolol can be increased when it is combined with Flecainide.Approved, Withdrawn
FloctafenineThe risk or severity of adverse effects can be increased when Floctafenine is combined with Metoprolol.Approved, Withdrawn
FluconazoleThe metabolism of Metoprolol can be decreased when combined with Fluconazole.Approved
FlunarizineThe metabolism of Flunarizine can be decreased when combined with Metoprolol.Approved
FlunixinFlunixin may decrease the antihypertensive activities of Metoprolol.Vet Approved
FluoxetineThe serum concentration of Metoprolol can be increased when it is combined with Fluoxetine.Approved, Vet Approved
FlupentixolThe serum concentration of Metoprolol can be increased when it is combined with Flupentixol.Approved, Withdrawn
FluphenazineThe serum concentration of Metoprolol can be increased when it is combined with Fluphenazine.Approved
FlurazepamThe serum concentration of Metoprolol can be increased when it is combined with Flurazepam.Approved, Illicit
FlurbiprofenFlurbiprofen may decrease the antihypertensive activities of Metoprolol.Approved, Investigational
Fluticasone furoateThe serum concentration of Fluticasone furoate can be increased when it is combined with Metoprolol.Approved
FluvastatinThe serum concentration of Metoprolol can be increased when it is combined with Fluvastatin.Approved
FluvoxamineThe serum concentration of Metoprolol can be increased when it is combined with Fluvoxamine.Approved, Investigational
FormoterolThe metabolism of Formoterol can be decreased when combined with Metoprolol.Approved, Investigational
FosinoprilThe risk or severity of adverse effects can be increased when Metoprolol is combined with Fosinopril.Approved
FosphenytoinThe metabolism of Metoprolol can be increased when combined with Fosphenytoin.Approved
FurazolidoneFurazolidone may increase the hypotensive activities of Metoprolol.Approved, Vet Approved
FurosemideThe risk or severity of adverse effects can be increased when Metoprolol is combined with Furosemide.Approved, Vet Approved
GalantamineGalantamine may increase the bradycardic activities of Metoprolol.Approved
Gallamine TriethiodideGallamine Triethiodide may increase the bradycardic activities of Metoprolol.Approved
GefitinibThe serum concentration of Metoprolol can be increased when it is combined with Gefitinib.Approved, Investigational
GemcitabineThe serum concentration of Gemcitabine can be increased when it is combined with Metoprolol.Approved
GemfibrozilThe metabolism of Metoprolol can be decreased when combined with Gemfibrozil.Approved
GenisteinThe serum concentration of Metoprolol can be increased when it is combined with Genistein.Investigational
Ginkgo bilobaGinkgo biloba may increase the bradycardic activities of Metoprolol.Approved, Nutraceutical
GlibornurideMetoprolol may increase the hypoglycemic activities of Glibornuride.Withdrawn
GliclazideMetoprolol may increase the hypoglycemic activities of Gliclazide.Approved
GlimepirideMetoprolol may increase the hypoglycemic activities of Glimepiride.Approved
GlipizideMetoprolol may increase the hypoglycemic activities of Glipizide.Approved
GliquidoneMetoprolol may increase the hypoglycemic activities of Gliquidone.Approved
GlisoxepideMetoprolol may increase the hypoglycemic activities of Glisoxepide.Approved
GlyburideThe serum concentration of Metoprolol can be increased when it is combined with Glyburide.Approved
GlycerolThe serum concentration of Metoprolol can be increased when it is combined with Glycerol.Experimental
Gramicidin DThe serum concentration of Metoprolol can be increased when it is combined with Gramicidin D.Approved
GranisetronThe serum concentration of Metoprolol can be increased when it is combined with Granisetron.Approved, Investigational
GrazoprevirThe serum concentration of Grazoprevir can be increased when it is combined with Metoprolol.Approved
GrepafloxacinThe serum concentration of Grepafloxacin can be increased when it is combined with Metoprolol.Withdrawn
GTS-21The risk or severity of adverse effects can be increased when Metoprolol is combined with GTS-21.Investigational
GuanabenzGuanabenz may increase the atrioventricular blocking (AV block) activities of Metoprolol.Approved
GuanadrelGuanadrel may increase the hypotensive activities of Metoprolol.Approved
GuanethidineMetoprolol may increase the hypotensive activities of Guanethidine.Approved
GuanfacineGuanfacine may increase the atrioventricular blocking (AV block) activities of Metoprolol.Approved, Investigational
HalofantrineThe serum concentration of Metoprolol can be increased when it is combined with Halofantrine.Approved
HaloperidolThe serum concentration of Metoprolol can be increased when it is combined with Haloperidol.Approved
HalothaneThe metabolism of Halothane can be decreased when combined with Metoprolol.Approved, Vet Approved
HexamethoniumMetoprolol may increase the hypotensive activities of Hexamethonium.Experimental
HexobarbitalHexobarbital may increase the hypotensive activities of Metoprolol.Approved
HigenamineHigenamine may decrease the antihypertensive activities of Metoprolol.Investigational
Histamine PhosphateThe serum concentration of Metoprolol can be increased when it is combined with Histamine Phosphate.Approved
HMPL-004HMPL-004 may decrease the antihypertensive activities of Metoprolol.Investigational
Huperzine AHuperzine A may increase the bradycardic activities of Metoprolol.Investigational
HydracarbazineHydracarbazine may increase the hypotensive activities of Metoprolol.Approved
HydralazineThe risk or severity of adverse effects can be increased when Metoprolol is combined with Hydralazine.Approved
HydrochlorothiazideThe risk or severity of adverse effects can be increased when Metoprolol is combined with Hydrochlorothiazide.Approved, Vet Approved
HydrocodoneThe metabolism of Hydrocodone can be decreased when combined with Metoprolol.Approved, Illicit
HydrocortisoneThe serum concentration of Hydrocortisone can be increased when it is combined with Metoprolol.Approved, Vet Approved
HydroflumethiazideMetoprolol may increase the hypotensive activities of Hydroflumethiazide.Approved
HydromorphoneThe metabolism of Hydromorphone can be decreased when combined with Metoprolol.Approved, Illicit
HydroxychloroquineThe serum concentration of Metoprolol can be increased when it is combined with Hydroxychloroquine.Approved
HydroxyureaThe serum concentration of Metoprolol can be increased when it is combined with Hydroxyurea.Approved
HydroxyzineThe serum concentration of Metoprolol can be increased when it is combined with Hydroxyzine.Approved
IbrutinibThe metabolism of Ibrutinib can be decreased when combined with Metoprolol.Approved
IbuprofenThe serum concentration of Ibuprofen can be increased when it is combined with Metoprolol.Approved
IbuproxamIbuproxam may decrease the antihypertensive activities of Metoprolol.Withdrawn
IcatibantIcatibant may decrease the antihypertensive activities of Metoprolol.Approved
IdarubicinThe serum concentration of Metoprolol can be increased when it is combined with Idarubicin.Approved
IdelalisibThe serum concentration of Idelalisib can be increased when it is combined with Metoprolol.Approved
IloperidoneThe metabolism of Iloperidone can be decreased when combined with Metoprolol.Approved
IloprostIloprost may increase the hypotensive activities of Metoprolol.Approved, Investigational
ImatinibThe serum concentration of Metoprolol can be increased when it is combined with Imatinib.Approved
ImidaprilThe risk or severity of adverse effects can be increased when Metoprolol is combined with Imidapril.Investigational
ImipramineThe serum concentration of Metoprolol can be increased when it is combined with Imipramine.Approved
IndacaterolThe serum concentration of Indacaterol can be increased when it is combined with Metoprolol.Approved
IndalpineThe serum concentration of Metoprolol can be increased when it is combined with Indalpine.Investigational, Withdrawn
IndapamideThe risk or severity of adverse effects can be increased when Metoprolol is combined with Indapamide.Approved
IndenololMetoprolol may increase the hypotensive activities of Indenolol.Withdrawn
IndinavirThe serum concentration of Metoprolol can be increased when it is combined with Indinavir.Approved
indisulamThe serum concentration of Metoprolol can be increased when it is combined with indisulam.Investigational
IndomethacinThe serum concentration of Metoprolol can be increased when it is combined with Indomethacin.Approved, Investigational
IndoprofenIndoprofen may decrease the antihypertensive activities of Metoprolol.Withdrawn
IndoraminMetoprolol may increase the orthostatic hypotensive activities of Indoramin.Withdrawn
Insulin PorkMetoprolol may increase the hypoglycemic activities of Insulin Pork.Approved
Ipratropium bromideThe metabolism of Ipratropium bromide can be decreased when combined with Metoprolol.Approved
IproclozideIproclozide may increase the hypotensive activities of Metoprolol.Withdrawn
IproniazidIproniazid may increase the hypotensive activities of Metoprolol.Withdrawn
IrbesartanThe serum concentration of Metoprolol can be increased when it is combined with Irbesartan.Approved, Investigational
IrinotecanThe serum concentration of Irinotecan can be increased when it is combined with Metoprolol.Approved, Investigational
IsavuconazoniumThe serum concentration of Metoprolol can be increased when it is combined with Isavuconazonium.Approved, Investigational
IsocarboxazidIsocarboxazid may increase the hypotensive activities of Metoprolol.Approved
IsoetarineMetoprolol may decrease the bronchodilatory activities of Isoetarine.Approved
IsofluraneThe risk or severity of adverse effects can be increased when Metoprolol is combined with Isoflurane.Approved, Vet Approved
IsoflurophateIsoflurophate may increase the bradycardic activities of Metoprolol.Approved, Withdrawn
IsoniazidThe serum concentration of Metoprolol can be increased when it is combined with Isoniazid.Approved
IsoprenalineMetoprolol may decrease the bronchodilatory activities of Isoprenaline.Approved
Isosorbide DinitrateThe risk or severity of adverse effects can be increased when Metoprolol is combined with Isosorbide Dinitrate.Approved
Isosorbide MononitrateThe risk or severity of adverse effects can be increased when Metoprolol is combined with Isosorbide Mononitrate.Approved
IsoxicamIsoxicam may decrease the antihypertensive activities of Metoprolol.Withdrawn
IsoxsuprineThe risk or severity of adverse effects can be increased when Metoprolol is combined with Isoxsuprine.Approved, Withdrawn
IsradipineThe risk or severity of adverse effects can be increased when Metoprolol is combined with Isradipine.Approved
ItraconazoleThe serum concentration of Metoprolol can be increased when it is combined with Itraconazole.Approved, Investigational
IvabradineMetoprolol may increase the bradycardic activities of Ivabradine.Approved
IvacaftorThe serum concentration of Metoprolol can be increased when it is combined with Ivacaftor.Approved
IvermectinThe serum concentration of Ivermectin can be increased when it is combined with Metoprolol.Approved, Vet Approved
IxazomibThe metabolism of Ixazomib can be decreased when combined with Metoprolol.Approved
KebuzoneKebuzone may decrease the antihypertensive activities of Metoprolol.Experimental
KetamineThe serum concentration of Metoprolol can be increased when it is combined with Ketamine.Approved, Vet Approved
KetanserinMetoprolol may increase the hypotensive activities of Ketanserin.Investigational
KetazolamThe serum concentration of Ketazolam can be increased when it is combined with Metoprolol.Approved
KetoconazoleThe serum concentration of Metoprolol can be increased when it is combined with Ketoconazole.Approved, Investigational
KetoprofenKetoprofen may decrease the antihypertensive activities of Metoprolol.Approved, Vet Approved
KetorolacKetorolac may decrease the antihypertensive activities of Metoprolol.Approved
LabetalolThe serum concentration of Metoprolol can be increased when it is combined with Labetalol.Approved
LacidipineMetoprolol may increase the hypotensive activities of Lacidipine.Approved
LacosamideMetoprolol may increase the atrioventricular blocking (AV block) activities of Lacosamide.Approved
LamivudineThe serum concentration of Lamivudine can be increased when it is combined with Metoprolol.Approved, Investigational
LamotrigineThe serum concentration of Lamotrigine can be increased when it is combined with Metoprolol.Approved, Investigational
LanreotideMetoprolol may increase the bradycardic activities of Lanreotide.Approved
LansoprazoleThe serum concentration of Metoprolol can be increased when it is combined with Lansoprazole.Approved, Investigational
LapatinibThe serum concentration of Metoprolol can be increased when it is combined with Lapatinib.Approved, Investigational
LatanoprostMetoprolol may increase the hypotensive activities of Latanoprost.Approved, Investigational
LedipasvirThe serum concentration of Ledipasvir can be increased when it is combined with Metoprolol.Approved
LeflunomideLeflunomide may decrease the antihypertensive activities of Metoprolol.Approved, Investigational
LenalidomideThe serum concentration of Lenalidomide can be increased when it is combined with Metoprolol.Approved
LenvatinibThe serum concentration of Lenvatinib can be increased when it is combined with Metoprolol.Approved
LercanidipineLercanidipine may increase the hypotensive activities of Metoprolol.Approved, Investigational
LevetiracetamThe serum concentration of Levetiracetam can be increased when it is combined with Metoprolol.Approved, Investigational
LevobunololThe risk or severity of adverse effects can be increased when Metoprolol is combined with Levobunolol.Approved
LevobupivacaineThe risk or severity of adverse effects can be increased when Metoprolol is combined with Levobupivacaine.Approved
LevodopaMetoprolol may increase the orthostatic hypotensive activities of Levodopa.Approved
LevofloxacinThe serum concentration of Levofloxacin can be increased when it is combined with Metoprolol.Approved, Investigational
LevomilnacipranThe serum concentration of Levomilnacipran can be increased when it is combined with Metoprolol.Approved
LevosimendanThe risk or severity of adverse effects can be increased when Metoprolol is combined with Levosimendan.Approved, Investigational
LevothyroxineThe serum concentration of Metoprolol can be decreased when it is combined with Levothyroxine.Approved
LidocaineThe serum concentration of Metoprolol can be increased when it is combined with Lidocaine.Approved, Vet Approved
LinagliptinThe serum concentration of Linagliptin can be increased when it is combined with Metoprolol.Approved
LiothyronineThe serum concentration of Metoprolol can be decreased when it is combined with Liothyronine.Approved, Vet Approved
LiotrixThe serum concentration of Metoprolol can be decreased when it is combined with Liotrix.Approved
LisinoprilThe risk or severity of adverse effects can be increased when Metoprolol is combined with Lisinopril.Approved, Investigational
LisofyllineLisofylline may decrease the antihypertensive activities of Metoprolol.Investigational
LisurideThe metabolism of Lisuride can be decreased when combined with Metoprolol.Approved
LobelineThe risk or severity of adverse effects can be increased when Metoprolol is combined with Lobeline.Investigational
LofexidineLofexidine may increase the atrioventricular blocking (AV block) activities of Metoprolol.Approved, Investigational
LomitapideThe serum concentration of Metoprolol can be increased when it is combined with Lomitapide.Approved
LomustineThe serum concentration of Metoprolol can be increased when it is combined with Lomustine.Approved
LoperamideThe serum concentration of Loperamide can be increased when it is combined with Metoprolol.Approved
LopinavirThe serum concentration of Metoprolol can be increased when it is combined with Lopinavir.Approved
LoratadineThe serum concentration of Metoprolol can be increased when it is combined with Loratadine.Approved
LorcaserinThe metabolism of Lorcaserin can be decreased when combined with Metoprolol.Approved
LornoxicamLornoxicam may decrease the antihypertensive activities of Metoprolol.Approved
LosartanThe risk or severity of adverse effects can be increased when Metoprolol is combined with Losartan.Approved
LovastatinThe serum concentration of Metoprolol can be increased when it is combined with Lovastatin.Approved, Investigational
LoxoprofenLoxoprofen may decrease the antihypertensive activities of Metoprolol.Approved
LucinactantMetoprolol may increase the bradycardic activities of Lucinactant.Approved
LuliconazoleThe serum concentration of Metoprolol can be increased when it is combined with Luliconazole.Approved
LumacaftorThe serum concentration of Metoprolol can be decreased when it is combined with Lumacaftor.Approved
LumefantrineThe serum concentration of Metoprolol can be increased when it is combined with Lumefantrine.Approved
LumiracoxibLumiracoxib may decrease the antihypertensive activities of Metoprolol.Approved, Investigational
MacitentanMetoprolol may increase the hypotensive activities of Macitentan.Approved
Magnesium salicylateMagnesium salicylate may decrease the antihypertensive activities of Metoprolol.Approved
MalathionMalathion may increase the bradycardic activities of Metoprolol.Approved, Investigational
ManidipineMetoprolol may increase the hypotensive activities of Manidipine.Approved
MannitolThe risk or severity of adverse effects can be increased when Metoprolol is combined with Mannitol.Approved, Investigational
MaprotilineThe serum concentration of Metoprolol can be increased when it is combined with Maprotiline.Approved
MasoprocolMasoprocol may decrease the antihypertensive activities of Metoprolol.Approved
MebanazineMebanazine may increase the hypotensive activities of Metoprolol.Withdrawn
MebendazoleThe serum concentration of Metoprolol can be increased when it is combined with Mebendazole.Approved, Vet Approved
MecamylamineThe risk or severity of adverse effects can be increased when Metoprolol is combined with Mecamylamine.Approved
Meclofenamic acidMeclofenamic acid may decrease the antihypertensive activities of Metoprolol.Approved, Vet Approved
Mefenamic acidMefenamic acid may decrease the antihypertensive activities of Metoprolol.Approved
MefloquineThe serum concentration of Metoprolol can be increased when it is combined with Mefloquine.Approved
Megestrol acetateThe serum concentration of Metoprolol can be increased when it is combined with Megestrol acetate.Approved, Vet Approved
MeloxicamMeloxicam may decrease the antihypertensive activities of Metoprolol.Approved, Vet Approved
MemantineMemantine may increase the bradycardic activities of Metoprolol.Approved, Investigational
MephenytoinThe metabolism of Mephenytoin can be decreased when combined with Metoprolol.Investigational, Withdrawn
MepivacaineThe serum concentration of Mepivacaine can be increased when it is combined with Metoprolol.Approved, Vet Approved
MeprobamateThe serum concentration of Metoprolol can be increased when it is combined with Meprobamate.Approved, Illicit
MepyramineThe serum concentration of Metoprolol can be increased when it is combined with Mepyramine.Approved, Vet Approved
MequitazineThe metabolism of Mequitazine can be decreased when combined with Metoprolol.Approved
MesalazineMesalazine may decrease the antihypertensive activities of Metoprolol.Approved
MesoridazineThe metabolism of Mesoridazine can be decreased when combined with Metoprolol.Approved
MetamizoleMetamizole may decrease the antihypertensive activities of Metoprolol.Withdrawn
MethacholineThe risk or severity of adverse effects can be increased when Metoprolol is combined with Methacholine.Approved
MethadoneThe serum concentration of Metoprolol can be increased when it is combined with Methadone.Approved
MethamphetamineThe serum concentration of Metoprolol can be increased when it is combined with Methamphetamine.Approved, Illicit
Methanesulfonyl FluorideMethanesulfonyl Fluoride may increase the bradycardic activities of Metoprolol.Investigational
MethazolamideThe serum concentration of Metoprolol can be increased when it is combined with Methazolamide.Approved
MethimazoleThe serum concentration of Metoprolol can be increased when it is combined with Methimazole.Approved
MethohexitalMethohexital may increase the hypotensive activities of Metoprolol.Approved
MethotrexateThe serum concentration of Methotrexate can be increased when it is combined with Metoprolol.Approved
MethotrimeprazineThe serum concentration of Metoprolol can be increased when it is combined with Methotrimeprazine.Approved
MethoxyfluraneThe metabolism of Methoxyflurane can be decreased when combined with Metoprolol.Approved, Vet Approved
MethyclothiazideThe risk or severity of adverse effects can be increased when Methyclothiazide is combined with Metoprolol.Approved
MethyldopaThe risk or severity of adverse effects can be increased when Metoprolol is combined with Methyldopa.Approved
Methylene blueMethylene blue may increase the hypotensive activities of Metoprolol.Investigational
MethylnaltrexoneThe serum concentration of Metoprolol can be increased when it is combined with Methylnaltrexone.Approved
MethylphenidateThe serum concentration of Metoprolol can be increased when it is combined with Methylphenidate.Approved, Investigational
MethylphenobarbitalMethylphenobarbital may increase the hypotensive activities of Metoprolol.Approved
MethylprednisoloneThe serum concentration of Methylprednisolone can be increased when it is combined with Metoprolol.Approved, Vet Approved
MethyprylonThe metabolism of Methyprylon can be decreased when combined with Metoprolol.Approved, Illicit, Withdrawn
MetipranololThe risk or severity of adverse effects can be increased when Metoprolol is combined with Metipranolol.Approved
MetoclopramideThe serum concentration of Metoprolol can be increased when it is combined with Metoclopramide.Approved, Investigational
MetolazoneThe risk or severity of adverse effects can be increased when Metoprolol is combined with Metolazone.Approved
MetyrosineMetoprolol may increase the hypotensive activities of Metyrosine.Approved
MexiletineThe metabolism of Mexiletine can be decreased when combined with Metoprolol.Approved
MianserinThe serum concentration of Metoprolol can be increased when it is combined with Mianserin.Approved
MibefradilThe serum concentration of Metoprolol can be increased when it is combined with Mibefradil.Withdrawn
MiconazoleThe serum concentration of Metoprolol can be increased when it is combined with Miconazole.Approved, Investigational, Vet Approved
MidazolamThe serum concentration of Metoprolol can be decreased when it is combined with Midazolam.Approved, Illicit
MidodrineThe serum concentration of Metoprolol can be increased when it is combined with Midodrine.Approved
MifepristoneThe serum concentration of Metoprolol can be increased when it is combined with Mifepristone.Approved, Investigational
MilnacipranThe serum concentration of Metoprolol can be increased when it is combined with Milnacipran.Approved
MinaprineMinaprine may increase the bradycardic activities of Metoprolol.Approved
MinoxidilThe risk or severity of adverse effects can be increased when Metoprolol is combined with Minoxidil.Approved
MirabegronMirabegron may decrease the antihypertensive activities of Metoprolol.Approved
MirtazapineThe serum concentration of Metoprolol can be increased when it is combined with Mirtazapine.Approved
MitomycinThe serum concentration of Metoprolol can be increased when it is combined with Mitomycin.Approved
MitoxantroneThe serum concentration of Metoprolol can be decreased when it is combined with Mitoxantrone.Approved, Investigational
MizoribineMizoribine may decrease the antihypertensive activities of Metoprolol.Investigational
MoclobemideThe serum concentration of Metoprolol can be increased when it is combined with Moclobemide.Approved
ModafinilThe metabolism of Metoprolol can be decreased when combined with Modafinil.Approved, Investigational
MoexiprilThe risk or severity of adverse effects can be increased when Metoprolol is combined with Moexipril.Approved
MolsidomineMolsidomine may increase the hypotensive activities of Metoprolol.Approved
MoricizineMoricizine may increase the hypotensive activities of Metoprolol.Approved, Withdrawn
MorphineThe serum concentration of Morphine can be increased when it is combined with Metoprolol.Approved, Investigational
MoxonidineMetoprolol may increase the hypotensive activities of Moxonidine.Approved
Mycophenolate mofetilThe serum concentration of Mycophenolate mofetil can be increased when it is combined with Metoprolol.Approved, Investigational
Mycophenolic acidMycophenolic acid may decrease the antihypertensive activities of Metoprolol.Approved
NabiloneThe risk or severity of adverse effects can be increased when Metoprolol is combined with Nabilone.Approved, Investigational
NabumetoneNabumetone may decrease the antihypertensive activities of Metoprolol.Approved
NadololThe risk or severity of adverse effects can be increased when Metoprolol is combined with Nadolol.Approved
NafamostatNafamostat may decrease the antihypertensive activities of Metoprolol.Investigational
NaftifineNaftifine may decrease the antihypertensive activities of Metoprolol.Approved
NaftopidilMetoprolol may increase the hypotensive activities of Naftopidil.Investigational
NaloxegolThe serum concentration of Metoprolol can be increased when it is combined with Naloxegol.Approved
NaloxoneThe serum concentration of Naloxone can be increased when it is combined with Metoprolol.Approved, Vet Approved
NaltrexoneThe serum concentration of Metoprolol can be increased when it is combined with Naltrexone.Approved, Investigational, Vet Approved
NaphazolineNaphazoline may increase the atrioventricular blocking (AV block) activities of Metoprolol.Approved
NaproxenNaproxen may decrease the antihypertensive activities of Metoprolol.Approved, Vet Approved
NaringeninThe serum concentration of Metoprolol can be increased when it is combined with Naringenin.Experimental
NateglinideThe metabolism of Nateglinide can be decreased when combined with Metoprolol.Approved, Investigational
NCX 4016NCX 4016 may decrease the antihypertensive activities of Metoprolol.Investigational
NebivololThe serum concentration of Nebivolol can be increased when it is combined with Metoprolol.Approved, Investigational
NefazodoneThe serum concentration of Metoprolol can be increased when it is combined with Nefazodone.Approved, Withdrawn
NelfinavirThe serum concentration of Metoprolol can be increased when it is combined with Nelfinavir.Approved
NeostigmineNeostigmine may increase the bradycardic activities of Metoprolol.Approved, Vet Approved
NepafenacNepafenac may decrease the antihypertensive activities of Metoprolol.Approved
NesiritideThe risk or severity of adverse effects can be increased when Metoprolol is combined with Nesiritide.Approved, Investigational
NetupitantThe metabolism of Netupitant can be decreased when combined with Metoprolol.Approved
NevirapineThe serum concentration of Metoprolol can be increased when it is combined with Nevirapine.Approved
NiacinThe serum concentration of Metoprolol can be increased when it is combined with Niacin.Approved, Investigational, Nutraceutical
NialamideNialamide may increase the hypotensive activities of Metoprolol.Withdrawn
NicardipineThe serum concentration of Metoprolol can be increased when it is combined with Nicardipine.Approved
NicergolineThe metabolism of Nicergoline can be decreased when combined with Metoprolol.Approved
NicorandilNicorandil may increase the hypotensive activities of Metoprolol.Approved
NicotinamideThe serum concentration of Metoprolol can be increased when it is combined with Nicotinamide.Approved
NicotineThe metabolism of Nicotine can be decreased when combined with Metoprolol.Approved
Nicotine bitartrateThe risk or severity of adverse effects can be increased when Metoprolol is combined with Nicotine bitartrate.Approved
NifedipineThe serum concentration of Metoprolol can be increased when it is combined with Nifedipine.Approved
Niflumic AcidNiflumic Acid may decrease the antihypertensive activities of Metoprolol.Approved
NiguldipineMetoprolol may increase the hypotensive activities of Niguldipine.Experimental
NilotinibThe serum concentration of Metoprolol can be increased when it is combined with Nilotinib.Approved, Investigational
NilvadipineMetoprolol may increase the hypotensive activities of Nilvadipine.Approved
NimesulideNimesulide may decrease the antihypertensive activities of Metoprolol.Approved, Withdrawn
NimodipineThe risk or severity of adverse effects can be increased when Metoprolol is combined with Nimodipine.Approved
NintedanibThe serum concentration of Nintedanib can be increased when it is combined with Metoprolol.Approved
NisoldipineThe risk or severity of adverse effects can be increased when Metoprolol is combined with Nisoldipine.Approved
NitrazepamThe serum concentration of Metoprolol can be increased when it is combined with Nitrazepam.Approved
NitrendipineThe serum concentration of Metoprolol can be increased when it is combined with Nitrendipine.Approved
Nitric OxideThe risk or severity of adverse effects can be increased when Metoprolol is combined with Nitric Oxide.Approved
NitroaspirinNitroaspirin may decrease the antihypertensive activities of Metoprolol.Investigational
NitrofuralThe metabolism of Nitrofural can be decreased when combined with Metoprolol.Approved, Vet Approved
NitroglycerinThe risk or severity of adverse effects can be increased when Metoprolol is combined with Nitroglycerin.Approved, Investigational
NitroprussideThe risk or severity of adverse effects can be increased when Metoprolol is combined with Nitroprusside.Approved
NizatidineThe serum concentration of Nizatidine can be increased when it is combined with Metoprolol.Approved
NorepinephrineNorepinephrine may increase the atrioventricular blocking (AV block) activities of Metoprolol.Approved
NorethisteroneThe serum concentration of Metoprolol can be decreased when it is combined with Norethisterone.Approved
NortriptylineThe serum concentration of Metoprolol can be increased when it is combined with Nortriptyline.Approved
ObinutuzumabMetoprolol may increase the hypotensive activities of Obinutuzumab.Approved
OctamoxinOctamoxin may increase the hypotensive activities of Metoprolol.Withdrawn
OctreotideOctreotide may increase the bradycardic activities of Metoprolol.Approved, Investigational
OlanzapineThe serum concentration of Metoprolol can be increased when it is combined with Olanzapine.Approved, Investigational
OlmesartanThe risk or severity of adverse effects can be increased when Metoprolol is combined with Olmesartan.Approved, Investigational
OlodaterolMetoprolol may decrease the bronchodilatory activities of Olodaterol.Approved
OlopatadineOlopatadine may decrease the antihypertensive activities of Metoprolol.Approved
OlsalazineOlsalazine may decrease the antihypertensive activities of Metoprolol.Approved
OmapatrilatMetoprolol may increase the hypotensive activities of Omapatrilat.Investigational
OmbitasvirThe serum concentration of Ombitasvir can be increased when it is combined with Metoprolol.Approved
OmeprazoleThe serum concentration of Metoprolol can be increased when it is combined with Omeprazole.Approved, Investigational, Vet Approved
OndansetronThe serum concentration of Metoprolol can be increased when it is combined with Ondansetron.Approved
OrciprenalineMetoprolol may decrease the bronchodilatory activities of Orciprenaline.Approved
OrgoteinOrgotein may decrease the antihypertensive activities of Metoprolol.Vet Approved
OsimertinibThe serum concentration of Osimertinib can be increased when it is combined with Metoprolol.Approved
OuabainMetoprolol may increase the bradycardic activities of Ouabain.Approved
OxamniquineThe serum concentration of Metoprolol can be increased when it is combined with Oxamniquine.Approved
OxaprozinOxaprozin may decrease the antihypertensive activities of Metoprolol.Approved
OxprenololThe serum concentration of Metoprolol can be increased when it is combined with Oxprenolol.Approved
OxybutyninThe serum concentration of Metoprolol can be increased when it is combined with Oxybutynin.Approved, Investigational
OxycodoneThe metabolism of Oxycodone can be decreased when combined with Metoprolol.Approved, Illicit, Investigational
OxymetazolineOxymetazoline may increase the atrioventricular blocking (AV block) activities of Metoprolol.Approved
OxymetholoneThe serum concentration of Metoprolol can be increased when it is combined with Oxymetholone.Approved, Illicit
OxymorphoneThe metabolism of Oxymorphone can be decreased when combined with Metoprolol.Approved, Investigational, Vet Approved
OxyphenbutazoneOxyphenbutazone may decrease the antihypertensive activities of Metoprolol.Withdrawn
P-NitrophenolThe serum concentration of Metoprolol can be increased when it is combined with P-Nitrophenol.Experimental
PaclitaxelThe serum concentration of Metoprolol can be increased when it is combined with Paclitaxel.Approved, Vet Approved
PaliperidonePaliperidone may increase the atrioventricular blocking (AV block) activities of Metoprolol.Approved
Palmitic AcidThe serum concentration of Metoprolol can be increased when it is combined with Palmitic Acid.Experimental
PalonosetronThe metabolism of Palonosetron can be decreased when combined with Metoprolol.Approved, Investigational
PanobinostatThe serum concentration of Metoprolol can be increased when it is combined with Panobinostat.Approved, Investigational
PantoprazoleThe serum concentration of Metoprolol can be increased when it is combined with Pantoprazole.Approved
PapaverineThe risk or severity of adverse effects can be increased when Metoprolol is combined with Papaverine.Approved
ParecoxibParecoxib may decrease the antihypertensive activities of Metoprolol.Approved
PargylinePargyline may increase the hypotensive activities of Metoprolol.Approved
ParoxetineThe serum concentration of Metoprolol can be increased when it is combined with Paroxetine.Approved, Investigational
PasireotideMetoprolol may increase the bradycardic activities of Pasireotide.Approved
PazopanibThe serum concentration of Pazopanib can be increased when it is combined with Metoprolol.Approved
Peginterferon alfa-2bThe serum concentration of Metoprolol can be decreased when it is combined with Peginterferon alfa-2b.Approved
PenbutololThe risk or severity of adverse effects can be increased when Metoprolol is combined with Penbutolol.Approved, Investigational
PentamidineThe metabolism of Pentamidine can be decreased when combined with Metoprolol.Approved
PentobarbitalPentobarbital may increase the hypotensive activities of Metoprolol.Approved, Vet Approved
PentoliniumMetoprolol may increase the hypotensive activities of Pentolinium.Approved
PentoxifyllinePentoxifylline may increase the hypotensive activities of Metoprolol.Approved, Investigational
PerazinePerazine may increase the hypotensive activities of Metoprolol.Investigational
PergolideThe serum concentration of Metoprolol can be increased when it is combined with Pergolide.Approved, Vet Approved, Withdrawn
PerhexilineThe serum concentration of Metoprolol can be increased when it is combined with Perhexiline.Approved
PerindoprilThe risk or severity of adverse effects can be increased when Metoprolol is combined with Perindopril.Approved
PerphenazineThe serum concentration of Metoprolol can be increased when it is combined with Perphenazine.Approved
PethidineThe metabolism of Pethidine can be decreased when combined with Metoprolol.Approved
PhenacetinThe metabolism of Phenacetin can be decreased when combined with Metoprolol.Withdrawn
PhenelzinePhenelzine may increase the hypotensive activities of Metoprolol.Approved
PhenforminThe metabolism of Phenformin can be decreased when combined with Metoprolol.Approved, Withdrawn
PheniprazinePheniprazine may increase the hypotensive activities of Metoprolol.Withdrawn
PhenobarbitalThe serum concentration of Metoprolol can be decreased when it is combined with Phenobarbital.Approved
PhenoxybenzamineMetoprolol may increase the hypotensive activities of Phenoxybenzamine.Approved
PhenoxypropazinePhenoxypropazine may increase the hypotensive activities of Metoprolol.Withdrawn
PhentermineThe serum concentration of Metoprolol can be increased when it is combined with Phentermine.Approved, Illicit
PhentolamineMetoprolol may increase the hypotensive activities of Phentolamine.Approved
PhenylbutazonePhenylbutazone may decrease the antihypertensive activities of Metoprolol.Approved, Vet Approved
PhenylpropanolaminePhenylpropanolamine may increase the atrioventricular blocking (AV block) activities of Metoprolol.Approved, Vet Approved, Withdrawn
PhenytoinThe metabolism of Metoprolol can be increased when combined with Phenytoin.Approved, Vet Approved
PhysostigminePhysostigmine may increase the bradycardic activities of Metoprolol.Approved
PilocarpineThe risk or severity of adverse effects can be increased when Metoprolol is combined with Pilocarpine.Approved
PimecrolimusPimecrolimus may decrease the antihypertensive activities of Metoprolol.Approved, Investigational
PimozideThe serum concentration of Metoprolol can be increased when it is combined with Pimozide.Approved
PinacidilMetoprolol may increase the hypotensive activities of Pinacidil.Withdrawn
PindololThe serum concentration of Metoprolol can be increased when it is combined with Pindolol.Approved
PioglitazoneThe serum concentration of Metoprolol can be increased when it is combined with Pioglitazone.Approved, Investigational
PipamperoneThe risk or severity of adverse effects can be increased when Metoprolol is combined with Pipamperone.Approved
PiperazineThe metabolism of Piperazine can be decreased when combined with Metoprolol.Approved, Vet Approved
PipotiazineThe serum concentration of Metoprolol can be increased when it is combined with Pipotiazine.Approved
PirbuterolMetoprolol may decrease the bronchodilatory activities of Pirbuterol.Approved
PirfenidonePirfenidone may decrease the antihypertensive activities of Metoprolol.Investigational
PirlindolePirlindole may increase the hypotensive activities of Metoprolol.Approved
PiroxicamPiroxicam may decrease the antihypertensive activities of Metoprolol.Approved, Investigational
PitavastatinThe serum concentration of Pitavastatin can be increased when it is combined with Metoprolol.Approved
PivhydrazinePivhydrazine may increase the hypotensive activities of Metoprolol.Withdrawn
Platelet Activating FactorThe serum concentration of Metoprolol can be decreased when it is combined with Platelet Activating Factor.Experimental
PolythiazideMetoprolol may increase the hypotensive activities of Polythiazide.Approved
PomalidomideThe serum concentration of Pomalidomide can be increased when it is combined with Metoprolol.Approved
PonatinibThe serum concentration of Ponatinib can be increased when it is combined with Metoprolol.Approved
Poractant alfaMetoprolol may increase the bradycardic activities of Poractant alfa.Approved
PosaconazoleThe serum concentration of Metoprolol can be increased when it is combined with Posaconazole.Approved, Investigational, Vet Approved
PramipexoleThe risk or severity of adverse effects can be increased when Metoprolol is combined with Pramipexole.Approved, Investigational
PravastatinThe serum concentration of Metoprolol can be increased when it is combined with Pravastatin.Approved
PraziquantelThe serum concentration of Metoprolol can be increased when it is combined with Praziquantel.Approved, Vet Approved
PrazosinMetoprolol may increase the orthostatic hypotensive activities of Prazosin.Approved
PrednisoloneThe serum concentration of Prednisolone can be increased when it is combined with Metoprolol.Approved, Vet Approved
PrednisoneThe serum concentration of Prednisone can be increased when it is combined with Metoprolol.Approved, Vet Approved
PrimaquineThe serum concentration of Metoprolol can be increased when it is combined with Primaquine.Approved
PrimidonePrimidone may increase the hypotensive activities of Metoprolol.Approved, Vet Approved
ProbenecidThe serum concentration of Metoprolol can be increased when it is combined with Probenecid.Approved
ProcainamideThe metabolism of Procainamide can be decreased when combined with Metoprolol.Approved
ProcaterolMetoprolol may decrease the bronchodilatory activities of Procaterol.Approved
ProchlorperazineThe metabolism of Prochlorperazine can be decreased when combined with Metoprolol.Approved, Vet Approved
ProgesteroneThe serum concentration of Metoprolol can be decreased when it is combined with Progesterone.Approved, Vet Approved
ProguanilThe serum concentration of Metoprolol can be increased when it is combined with Proguanil.Approved
PromazineThe metabolism of Metoprolol can be decreased when combined with Promazine.Approved, Vet Approved
PromethazineThe serum concentration of Metoprolol can be increased when it is combined with Promethazine.Approved
PropacetamolPropacetamol may decrease the antihypertensive activities of Metoprolol.Approved
PropafenoneThe serum concentration of Metoprolol can be increased when it is combined with Propafenone.Approved
PropiopromazinePropiopromazine may increase the hypotensive activities of Metoprolol.Vet Approved
PropofolThe serum concentration of Metoprolol can be increased when it is combined with Propofol.Approved, Investigational, Vet Approved
PropranololThe serum concentration of Metoprolol can be increased when it is combined with Propranolol.Approved, Investigational
ProtriptylineThe serum concentration of Metoprolol can be increased when it is combined with Protriptyline.Approved
PrucaloprideThe serum concentration of Prucalopride can be increased when it is combined with Metoprolol.Approved
PseudoephedrinePseudoephedrine may increase the atrioventricular blocking (AV block) activities of Metoprolol.Approved
PTC299PTC299 may decrease the antihypertensive activities of Metoprolol.Investigational
PyridostigminePyridostigmine may increase the bradycardic activities of Metoprolol.Approved
PyrimethamineThe serum concentration of Metoprolol can be increased when it is combined with Pyrimethamine.Approved, Vet Approved
QuercetinThe serum concentration of Metoprolol can be increased when it is combined with Quercetin.Experimental
QuetiapineThe serum concentration of Metoprolol can be increased when it is combined with Quetiapine.Approved
QuinacrineThe serum concentration of Metoprolol can be increased when it is combined with Quinacrine.Approved
QuinaprilThe risk or severity of adverse effects can be increased when Metoprolol is combined with Quinapril.Approved, Investigational
QuinidineThe serum concentration of Metoprolol can be increased when it is combined with Quinidine.Approved
QuinineThe serum concentration of Metoprolol can be increased when it is combined with Quinine.Approved
RabeprazoleThe serum concentration of Metoprolol can be increased when it is combined with Rabeprazole.Approved, Investigational
RamiprilThe risk or severity of adverse effects can be increased when Ramipril is combined with Metoprolol.Approved
RanitidineThe serum concentration of Metoprolol can be increased when it is combined with Ranitidine.Approved
RanolazineThe serum concentration of Metoprolol can be increased when it is combined with Ranolazine.Approved, Investigational
RasagilineRasagiline may increase the hypotensive activities of Metoprolol.Approved
ReboxetineThe serum concentration of Metoprolol can be increased when it is combined with Reboxetine.Approved, Investigational
RegorafenibRegorafenib may increase the bradycardic activities of Metoprolol.Approved
RemifentanilThe risk or severity of adverse effects can be increased when Metoprolol is combined with Remifentanil.Approved
RemikirenRemikiren may increase the hypotensive activities of Metoprolol.Approved
RemoxiprideThe metabolism of Remoxipride can be decreased when combined with Metoprolol.Approved, Withdrawn
repinotanThe metabolism of repinotan can be decreased when combined with Metoprolol.Investigational
RescinnamineMetoprolol may increase the hypotensive activities of Rescinnamine.Approved
ReserpineReserpine may increase the hypotensive activities of Metoprolol.Approved
ResveratrolResveratrol may decrease the antihypertensive activities of Metoprolol.Experimental, Investigational
RifampicinThe metabolism of Metoprolol can be increased when combined with Rifampicin.Approved
RifapentineThe serum concentration of Metoprolol can be decreased when it is combined with Rifapentine.Approved
RifaximinThe serum concentration of Rifaximin can be increased when it is combined with Metoprolol.Approved, Investigational
RilmenidineMetoprolol may increase the hypotensive activities of Rilmenidine.Investigational
RilpivirineThe serum concentration of Metoprolol can be increased when it is combined with Rilpivirine.Approved
RiociguatThe risk or severity of adverse effects can be increased when Metoprolol is combined with Riociguat.Approved
RisperidoneThe serum concentration of Metoprolol can be increased when it is combined with Risperidone.Approved, Investigational
RitodrineMetoprolol may decrease the bronchodilatory activities of Ritodrine.Approved
RitonavirThe serum concentration of Metoprolol can be increased when it is combined with Ritonavir.Approved, Investigational
RituximabMetoprolol may increase the hypotensive activities of Rituximab.Approved
RivaroxabanThe serum concentration of Rivaroxaban can be increased when it is combined with Metoprolol.Approved
RivastigmineRivastigmine may increase the bradycardic activities of Metoprolol.Approved, Investigational
RofecoxibRofecoxib may decrease the antihypertensive activities of Metoprolol.Investigational, Withdrawn
RolapitantThe serum concentration of Metoprolol can be increased when it is combined with Rolapitant.Approved
RomidepsinThe serum concentration of Romidepsin can be increased when it is combined with Metoprolol.Approved, Investigational
RopiniroleThe serum concentration of Metoprolol can be increased when it is combined with Ropinirole.Approved, Investigational
RopivacaineThe metabolism of Ropivacaine can be decreased when combined with Metoprolol.Approved
RosiglitazoneThe serum concentration of Metoprolol can be increased when it is combined with Rosiglitazone.Approved, Investigational
RotigotineThe serum concentration of Metoprolol can be increased when it is combined with Rotigotine.Approved
RutinThe serum concentration of Metoprolol can be increased when it is combined with Rutin.Experimental
RuxolitinibRuxolitinib may increase the bradycardic activities of Metoprolol.Approved
SacubitrilThe risk or severity of adverse effects can be increased when Metoprolol is combined with Sacubitril.Approved
SafrazineSafrazine may increase the hypotensive activities of Metoprolol.Withdrawn
SalbutamolMetoprolol may decrease the bronchodilatory activities of Salbutamol.Approved, Vet Approved
SalicylamideSalicylamide may decrease the antihypertensive activities of Metoprolol.Approved
Salicylic acidThe serum concentration of Salicylic acid can be increased when it is combined with Metoprolol.Approved, Vet Approved
SalmeterolMetoprolol may decrease the bronchodilatory activities of Salmeterol.Approved
SalsalateSalsalate may decrease the antihypertensive activities of Metoprolol.Approved
SaprisartanMetoprolol may increase the hypotensive activities of Saprisartan.Experimental
SaquinavirThe serum concentration of Metoprolol can be increased when it is combined with Saquinavir.Approved, Investigational
ScopolamineThe serum concentration of Metoprolol can be increased when it is combined with Scopolamine.Approved
SecobarbitalSecobarbital may increase the hypotensive activities of Metoprolol.Approved, Vet Approved
SelegilineThe serum concentration of Metoprolol can be increased when it is combined with Selegiline.Approved, Investigational, Vet Approved
SelexipagThe serum concentration of Selexipag can be increased when it is combined with Metoprolol.Approved
SeratrodastSeratrodast may decrease the antihypertensive activities of Metoprolol.Approved, Investigational
SertindoleThe metabolism of Sertindole can be decreased when combined with Metoprolol.Approved, Withdrawn
SertralineThe serum concentration of Metoprolol can be increased when it is combined with Sertraline.Approved
SevofluraneThe risk or severity of adverse effects can be increased when Metoprolol is combined with Sevoflurane.Approved, Vet Approved
SildenafilThe serum concentration of Metoprolol can be increased when it is combined with Sildenafil.Approved, Investigational
SilodosinThe serum concentration of Silodosin can be increased when it is combined with Metoprolol.Approved
SimeprevirThe serum concentration of Simeprevir can be increased when it is combined with Metoprolol.Approved
SimvastatinThe serum concentration of Metoprolol can be increased when it is combined with Simvastatin.Approved
SirolimusThe serum concentration of Metoprolol can be decreased when it is combined with Sirolimus.Approved, Investigational
SitagliptinThe serum concentration of Sitagliptin can be increased when it is combined with Metoprolol.Approved, Investigational
SitaxentanMetoprolol may increase the hypotensive activities of Sitaxentan.Approved, Investigational, Withdrawn
Sodium NitriteThe risk or severity of adverse effects can be increased when Metoprolol is combined with Sodium Nitrite.Approved
SofosbuvirThe serum concentration of Sofosbuvir can be increased when it is combined with Metoprolol.Approved
SorafenibThe serum concentration of Metoprolol can be increased when it is combined with Sorafenib.Approved, Investigational
SotalolThe risk or severity of adverse effects can be increased when Metoprolol is combined with Sotalol.Approved
SparfloxacinThe serum concentration of Sparfloxacin can be increased when it is combined with Metoprolol.Approved
SparteineThe serum concentration of Metoprolol can be increased when it is combined with Sparteine.Experimental
SphingosineThe serum concentration of Sphingosine can be increased when it is combined with Metoprolol.Experimental
SpiraprilMetoprolol may increase the hypotensive activities of Spirapril.Approved
SpironolactoneThe risk or severity of adverse effects can be increased when Metoprolol is combined with Spironolactone.Approved
SRT501SRT501 may decrease the antihypertensive activities of Metoprolol.Investigational
St. John's WortThe serum concentration of Metoprolol can be decreased when it is combined with St. John's Wort.Nutraceutical
StaurosporineThe serum concentration of Metoprolol can be increased when it is combined with Staurosporine.Experimental
StiripentolThe metabolism of Metoprolol can be decreased when combined with Stiripentol.Approved
StreptokinaseThe risk or severity of adverse effects can be increased when Metoprolol is combined with Streptokinase.Approved
StreptozocinThe serum concentration of Metoprolol can be decreased when it is combined with Streptozocin.Approved
SufentanilMetoprolol may increase the bradycardic activities of Sufentanil.Approved, Investigational
SulfanilamideThe serum concentration of Metoprolol can be increased when it is combined with Sulfanilamide.Approved
SulfaphenazoleThe serum concentration of Metoprolol can be increased when it is combined with Sulfaphenazole.Approved
SulfasalazineSulfasalazine may decrease the antihypertensive activities of Metoprolol.Approved
SulfinpyrazoneThe serum concentration of Metoprolol can be increased when it is combined with Sulfinpyrazone.Approved
SulindacSulindac may decrease the antihypertensive activities of Metoprolol.Approved
SumatriptanThe serum concentration of Metoprolol can be increased when it is combined with Sumatriptan.Approved, Investigational
SunitinibThe serum concentration of Metoprolol can be increased when it is combined with Sunitinib.Approved, Investigational
SuprofenSuprofen may decrease the antihypertensive activities of Metoprolol.Approved, Withdrawn
TacrineTacrine may increase the bradycardic activities of Metoprolol.Withdrawn
TacrolimusThe serum concentration of Metoprolol can be decreased when it is combined with Tacrolimus.Approved, Investigational
TadalafilTadalafil may increase the antihypertensive activities of Metoprolol.Approved, Investigational
TamoxifenThe serum concentration of Metoprolol can be increased when it is combined with Tamoxifen.Approved
TamsulosinMetoprolol may increase the orthostatic hypotensive activities of Tamsulosin.Approved, Investigational
TapentadolThe serum concentration of Metoprolol can be increased when it is combined with Tapentadol.Approved
Taurocholic AcidThe serum concentration of Taurocholic Acid can be increased when it is combined with Metoprolol.Experimental
Technetium Tc-99m sestamibiThe serum concentration of Technetium Tc-99m sestamibi can be increased when it is combined with Metoprolol.Approved
TegaserodThe serum concentration of Metoprolol can be increased when it is combined with Tegaserod.Investigational, Withdrawn
TelaprevirThe serum concentration of Telaprevir can be increased when it is combined with Metoprolol.Approved
TelithromycinThe serum concentration of Metoprolol can be increased when it is combined with Telithromycin.Approved
TelmisartanThe risk or severity of adverse effects can be increased when Metoprolol is combined with Telmisartan.Approved, Investigational
TemocaprilMetoprolol may increase the hypotensive activities of Temocapril.Experimental, Investigational
TemsirolimusThe serum concentration of Metoprolol can be increased when it is combined with Temsirolimus.Approved
TenoxicamTenoxicam may decrease the antihypertensive activities of Metoprolol.Approved
TepoxalinTepoxalin may decrease the antihypertensive activities of Metoprolol.Vet Approved
TerazosinMetoprolol may increase the orthostatic hypotensive activities of Terazosin.Approved
TerbinafineThe serum concentration of Metoprolol can be increased when it is combined with Terbinafine.Approved, Investigational, Vet Approved
TerbutalineMetoprolol may decrease the bronchodilatory activities of Terbutaline.Approved
TerfenadineThe serum concentration of Metoprolol can be increased when it is combined with Terfenadine.Withdrawn
TeriflunomideTeriflunomide may decrease the antihypertensive activities of Metoprolol.Approved
TerlipressinMetoprolol may increase the hypotensive activities of Terlipressin.Approved, Investigational
TesmilifeneThe serum concentration of Metoprolol can be decreased when it is combined with Tesmilifene.Investigational
TestosteroneThe serum concentration of Metoprolol can be increased when it is combined with Testosterone.Approved, Investigational
TetrabenazineThe metabolism of Tetrabenazine can be decreased when combined with Metoprolol.Approved
ThalidomideThe risk or severity of adverse effects can be increased when Metoprolol is combined with Thalidomide.Approved, Investigational, Withdrawn
TheophyllineThe metabolism of Theophylline can be decreased when combined with Metoprolol.Approved
ThiamylalThiamylal may increase the hypotensive activities of Metoprolol.Approved, Vet Approved
ThiethylperazineThiethylperazine may increase the hypotensive activities of Metoprolol.Withdrawn
ThiopentalThiopental may increase the hypotensive activities of Metoprolol.Approved, Vet Approved
ThioridazineThe serum concentration of Thioridazine can be increased when it is combined with Metoprolol.Approved
ThiothixeneThe serum concentration of Metoprolol can be increased when it is combined with Thiothixene.Approved
Tiaprofenic acidTiaprofenic acid may decrease the antihypertensive activities of Metoprolol.Approved
TiboloneMetoprolol may increase the hypotensive activities of Tibolone.Approved
TicagrelorThe serum concentration of Ticagrelor can be increased when it is combined with Metoprolol.Approved
TiclopidineThe serum concentration of Metoprolol can be increased when it is combined with Ticlopidine.Approved
TicrynafenMetoprolol may increase the hypotensive activities of Ticrynafen.Withdrawn
TimololThe risk or severity of adverse effects can be increased when Metoprolol is combined with Timolol.Approved
TinoridineTinoridine may decrease the antihypertensive activities of Metoprolol.Investigational
TiotropiumThe metabolism of Tiotropium can be decreased when combined with Metoprolol.Approved
TipranavirThe serum concentration of Metoprolol can be increased when it is combined with Tipranavir.Approved, Investigational
TizanidineTizanidine may increase the atrioventricular blocking (AV block) activities of Metoprolol.Approved
TofacitinibTofacitinib may increase the bradycardic activities of Metoprolol.Approved, Investigational
TolazamideMetoprolol may increase the hypoglycemic activities of Tolazamide.Approved
TolazolineMetoprolol may increase the hypotensive activities of Tolazoline.Approved, Vet Approved
TolbutamideMetoprolol may increase the hypoglycemic activities of Tolbutamide.Approved
TolcaponeThe risk or severity of adverse effects can be increased when Metoprolol is combined with Tolcapone.Approved, Withdrawn
Tolfenamic AcidTolfenamic Acid may decrease the antihypertensive activities of Metoprolol.Approved
TolmetinTolmetin may decrease the antihypertensive activities of Metoprolol.Approved
ToloxatoneToloxatone may increase the hypotensive activities of Metoprolol.Approved
TolterodineThe metabolism of Tolterodine can be decreased when combined with Metoprolol.Approved, Investigational
TolvaptanThe serum concentration of Tolvaptan can be increased when it is combined with Metoprolol.Approved
TopiramateThe metabolism of Metoprolol can be decreased when combined with Topiramate.Approved
TopotecanThe serum concentration of Topotecan can be increased when it is combined with Metoprolol.Approved, Investigational
TorasemideThe risk or severity of adverse effects can be increased when Torasemide is combined with Metoprolol.Approved
ToremifeneThe serum concentration of Toremifene can be increased when it is combined with Metoprolol.Approved, Investigational
TrabectedinThe metabolism of Trabectedin can be decreased when combined with Metoprolol.Approved, Investigational
TramadolThe serum concentration of Metoprolol can be increased when it is combined with Tramadol.Approved, Investigational
TrandolaprilThe risk or severity of adverse effects can be increased when Metoprolol is combined with Trandolapril.Approved
TranilastTranilast may decrease the antihypertensive activities of Metoprolol.Approved, Investigational
Trans-2-PhenylcyclopropylamineTrans-2-Phenylcyclopropylamine may increase the hypotensive activities of Metoprolol.Experimental
TranylcypromineThe serum concentration of Metoprolol can be increased when it is combined with Tranylcypromine.Approved
Trastuzumab emtansineThe serum concentration of Trastuzumab emtansine can be increased when it is combined with Metoprolol.Approved
TravoprostMetoprolol may increase the hypotensive activities of Travoprost.Approved
TrazodoneThe serum concentration of Metoprolol can be decreased when it is combined with Trazodone.Approved, Investigational
TreprostinilMetoprolol may increase the hypotensive activities of Treprostinil.Approved, Investigational
TretinoinThe risk or severity of adverse effects can be increased when Metoprolol is combined with Tretinoin.Approved, Investigational, Nutraceutical
TriamtereneThe risk or severity of adverse effects can be increased when Metoprolol is combined with Triamterene.Approved
TrichlorfonTrichlorfon may increase the bradycardic activities of Metoprolol.Vet Approved
TrichlormethiazideMetoprolol may increase the hypotensive activities of Trichlormethiazide.Approved, Vet Approved
TrifluoperazineThe serum concentration of Metoprolol can be increased when it is combined with Trifluoperazine.Approved
TriflupromazineThe serum concentration of Metoprolol can be increased when it is combined with Triflupromazine.Approved, Vet Approved
TrimazosinMetoprolol may increase the orthostatic hypotensive activities of Trimazosin.Experimental
TrimethaphanMetoprolol may increase the hypotensive activities of Trimethaphan.Approved
TrimethoprimThe serum concentration of Metoprolol can be decreased when it is combined with Trimethoprim.Approved, Vet Approved
TrimipramineThe serum concentration of Metoprolol can be increased when it is combined with Trimipramine.Approved
TripelennamineThe serum concentration of Metoprolol can be increased when it is combined with Tripelennamine.Approved, Vet Approved
TriprolidineThe serum concentration of Metoprolol can be increased when it is combined with Triprolidine.Approved
Trisalicylate-cholineTrisalicylate-choline may decrease the antihypertensive activities of Metoprolol.Approved
TroleandomycinThe serum concentration of Metoprolol can be increased when it is combined with Troleandomycin.Approved
TrospiumThe serum concentration of Metoprolol can be increased when it is combined with Trospium.Approved
TubocurarineTubocurarine may increase the bradycardic activities of Metoprolol.Approved
UdenafilUdenafil may increase the antihypertensive activities of Metoprolol.Approved, Investigational
UlipristalThe serum concentration of Ulipristal can be increased when it is combined with Metoprolol.Approved
UmeclidiniumThe serum concentration of Umeclidinium can be increased when it is combined with Metoprolol.Approved
UnoprostoneMetoprolol may increase the hypotensive activities of Unoprostone.Approved
ValdecoxibValdecoxib may decrease the antihypertensive activities of Metoprolol.Investigational, Withdrawn
ValsartanThe risk or severity of adverse effects can be increased when Valsartan is combined with Metoprolol.Approved, Investigational
VardenafilVardenafil may increase the antihypertensive activities of Metoprolol.Approved
VareniclineThe risk or severity of adverse effects can be increased when Metoprolol is combined with Varenicline.Approved, Investigational
VecuroniumThe serum concentration of Vecuronium can be increased when it is combined with Metoprolol.Approved
VemurafenibThe serum concentration of Metoprolol can be increased when it is combined with Vemurafenib.Approved
VenetoclaxThe serum concentration of Venetoclax can be increased when it is combined with Metoprolol.Approved
VenlafaxineThe serum concentration of Metoprolol can be increased when it is combined with Venlafaxine.Approved
VerapamilThe serum concentration of Metoprolol can be increased when it is combined with Verapamil.Approved
VilanterolMetoprolol may decrease the bronchodilatory activities of Vilanterol.Approved
VilazodoneThe metabolism of Vilazodone can be decreased when combined with Metoprolol.Approved
VinblastineThe serum concentration of Metoprolol can be increased when it is combined with Vinblastine.Approved
VincristineThe serum concentration of Vincristine can be increased when it is combined with Metoprolol.Approved, Investigational
VincristineThe serum concentration of Metoprolol can be decreased when it is combined with Vincristine.Approved, Investigational
VinorelbineThe serum concentration of Metoprolol can be increased when it is combined with Vinorelbine.Approved, Investigational
VinpocetineMetoprolol may increase the hypotensive activities of Vinpocetine.Investigational
VismodegibThe serum concentration of Vismodegib can be increased when it is combined with Metoprolol.Approved
VoriconazoleThe metabolism of Metoprolol can be decreased when combined with Voriconazole.Approved, Investigational
VortioxetineThe metabolism of Vortioxetine can be decreased when combined with Metoprolol.Approved
XylometazolineXylometazoline may increase the atrioventricular blocking (AV block) activities of Metoprolol.Approved
YohimbineThe serum concentration of Metoprolol can be increased when it is combined with Yohimbine.Approved, Vet Approved
ZafirlukastThe serum concentration of Metoprolol can be increased when it is combined with Zafirlukast.Approved, Investigational
ZalcitabineThe metabolism of Zalcitabine can be decreased when combined with Metoprolol.Approved
ZaltoprofenZaltoprofen may decrease the antihypertensive activities of Metoprolol.Approved
ZidovudineThe serum concentration of Zidovudine can be increased when it is combined with Metoprolol.Approved
ZileutonZileuton may decrease the antihypertensive activities of Metoprolol.Approved, Investigational, Withdrawn
ZimelidineThe serum concentration of Metoprolol can be increased when it is combined with Zimelidine.Withdrawn
ZiprasidoneThe serum concentration of Metoprolol can be increased when it is combined with Ziprasidone.Approved
ZolpidemThe metabolism of Zolpidem can be decreased when combined with Metoprolol.Approved
ZomepiracZomepirac may decrease the antihypertensive activities of Metoprolol.Withdrawn
ZuclopenthixolThe metabolism of Zuclopenthixol can be decreased when combined with Metoprolol.Approved, Investigational
Food Interactions
  • Avoid alcohol.
  • Avoid natural licorice.
  • Take with food.
References
Synthesis Reference

DrugSyn.org

US3998790
General References
  1. Authors unspecified: Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF) Lancet. 1999 Jun 12;353(9169):2001-7. [PubMed:10376614 ]
External Links
ATC CodesC07BB02C07AB02C07AB52C07BB52C07CB02C07FB02
AHFS Codes
  • 24:24.00
PDB EntriesNot Available
FDA labelDownload (439 KB)
MSDSDownload (73.9 KB)
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9854
Blood Brain Barrier-0.8426
Caco-2 permeable+0.6895
P-glycoprotein substrateSubstrate0.7317
P-glycoprotein inhibitor INon-inhibitor0.8182
P-glycoprotein inhibitor IINon-inhibitor0.8382
Renal organic cation transporterNon-inhibitor0.8418
CYP450 2C9 substrateNon-substrate0.81
CYP450 2D6 substrateSubstrate0.8918
CYP450 3A4 substrateNon-substrate0.6527
CYP450 1A2 substrateNon-inhibitor0.7018
CYP450 2C9 inhibitorNon-inhibitor0.8691
CYP450 2D6 inhibitorNon-inhibitor0.7909
CYP450 2C19 inhibitorNon-inhibitor0.9555
CYP450 3A4 inhibitorNon-inhibitor0.9476
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.9897
Ames testNon AMES toxic0.9163
CarcinogenicityNon-carcinogens0.9387
BiodegradationNot ready biodegradable0.8544
Rat acute toxicity1.9180 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.8368
hERG inhibition (predictor II)Non-inhibitor0.8202
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
Manufacturers
  • Novartis pharmaceuticals corp
  • Kv pharmaceutical co
  • Sandoz inc
  • Watson laboratories inc florida
  • Wockhardt ltd
  • Astrazeneca lp
  • Bedford laboratories
  • Hikma farmaceutica (portugal) sa
  • Hospira inc
  • Luitpold pharmaceuticals inc
  • Sagent strides llc
  • Sandoz canada inc
  • Watson laboratories inc
  • Apothecon inc div bristol myers squibb
  • Aurobindo pharma ltd
  • Caraco pharmaceutical laboratories ltd
  • Ipca laboratories ltd
  • Mutual pharmaceutical co inc
  • Mylan pharmaceuticals inc
  • Purepac pharmaceutical co
  • Solco healthcare us llc
  • Teva pharmaceuticals usa inc
  • Teva pharmaceuticals usa
Packagers
Dosage forms
FormRouteStrength
TabletOral25 mg
Tablet, film coatedOral
Kit
LiquidIntravenous1 mg
Tablet, extended releaseOral100 mg
Tablet, extended releaseOral200 mg
Injection, solutionIntravenous5 mg/5mL
TabletOral100 mg/1
TabletOral50 mg/1
InjectionIntravenous5 mg/5mL
Tablet, extended releaseOral100 mg/1
Tablet, extended releaseOral200 mg/1
Tablet, extended releaseOral25 mg/1
Tablet, extended releaseOral50 mg/1
Tablet, film coated, extended releaseOral100 mg/1
Tablet, film coated, extended releaseOral200 mg/1
Tablet, film coated, extended releaseOral25 mg/1
Tablet, film coated, extended releaseOral25 mg/301
Tablet, film coated, extended releaseOral50 mg/1
Tablet, film coated, extended releaseOral50 mg/301
Tablet, film coated, extended releaseOral190 mg/1
Tablet, film coated, extended releaseOral23.75 mg/1
Tablet, film coated, extended releaseOral47.5 mg/1
Tablet, film coated, extended releaseOral90 mg/1
Injection, solutionIntravenous1 mg/mL
TabletOral25 mg/1
Tablet, film coatedOral100 mg/1
Tablet, film coatedOral25 mg/1
Tablet, film coatedOral37.5 mg/1
Tablet, film coatedOral50 mg/1
Tablet, film coatedOral75 mg/1
TabletOral
SolutionIntravenous1 mg
TabletOral100 mg
TabletOral50 mg
Prices
Unit descriptionCostUnit
Metoprolol tartrate powder5.51USD g
Lopressor 5 mg/5 ml ampul3.85USD ml
Lopressor hct 100-25 tablet3.21USD tablet
Toprol XL 200 mg 24 Hour tablet3.08USD tablet
Lopressor HCT 100-50 mg tablet3.06USD tablet
Toprol xl 200 mg tablet2.96USD tablet
Lopressor hct 100-50 tablet2.82USD tablet
Lopressor 100 mg tablet2.75USD tablet
Metoprolol Succinate 200 mg 24 Hour tablet2.62USD tablet
Metoprolol succ er 200 mg tablet2.29USD tablet
Lopressor HCT 100-25 mg tablet2.21USD tablet
Lopressor HCT 50-25 mg tablet2.14USD tablet
Lopressor hct 50-25 tablet2.06USD tablet
Toprol XL 100 mg 24 Hour tablet1.93USD tablet
Toprol xl 100 mg tablet1.86USD tablet
Lopressor 50 mg tablet1.81USD tablet
Metoprolol Succinate 100 mg 24 Hour tablet1.53USD tablet
Metoprolol succ er 100 mg tablet1.44USD tablet
Toprol XL 25 mg 24 Hour tablet1.43USD tablet
Toprol XL 50 mg 24 Hour tablet1.43USD tablet
Lopresor 1 mg/ml1.29USD ml
Toprol xl 25 mg tablet1.24USD tablet
Toprol xl 50 mg tablet1.24USD tablet
Metoprolol Succinate 25 mg 24 Hour tablet1.17USD tablet
Metoprolol Succinate 50 mg 24 Hour tablet1.13USD tablet
Metoprolol succ er 50 mg tablet0.9USD tablet
Metoprolol succ er 25 mg tablet0.87USD tablet
Metoprolol tartrate 100 mg tablet0.8USD tablet
Toprol xl 100 mg tablet sa0.8USD tablet
Lopresor 100 mg Tablet0.61USD tablet
Lopresor Sr 200 mg Sustained-Release Tablet0.61USD tablet
Metoprolol tartrate 50 mg tablet0.56USD tablet
Metoprolol tartrate 25 mg tablet0.34USD tablet
Apo-Metoprolol Sr 200 mg Sustained-Release Tablet0.34USD tablet
Lopresor Sr 100 mg Sustained-Release Tablet0.34USD tablet
Sandoz Metoprolol Sr 200 mg Sustained-Release Tablet0.34USD tablet
Lopresor 50 mg Tablet0.3USD tablet
Apo-Metoprolol (Type L) 100 mg Tablet0.23USD tablet
Apo-Metoprolol 100 mg Tablet0.23USD tablet
Mylan-Metoprolol (Type L) 100 mg Tablet0.23USD tablet
Novo-Metoprol (Fc) 100 mg Tablet0.23USD tablet
Novo-Metoprol 100 mg Tablet0.23USD tablet
Nu-Metop 100 mg Tablet0.23USD tablet
Pms-Metoprolol-L 100 mg Tablet0.23USD tablet
Sandoz Metoprolol (Type L) 100 mg Tablet0.23USD tablet
Apo-Metoprolol Sr 100 mg Sustained-Release Tablet0.19USD tablet
Sandoz Metoprolol Sr 100 mg Sustained-Release Tablet0.19USD tablet
Apo-Metoprolol (Type L) 50 mg Tablet0.13USD tablet
Apo-Metoprolol 50 mg Tablet0.13USD tablet
Mylan-Metoprolol (Type L) 50 mg Tablet0.13USD tablet
Novo-Metoprol (Fc) 50 mg Tablet0.13USD tablet
Novo-Metoprol 50 mg Tablet0.13USD tablet
Nu-Metop 50 mg Tablet0.13USD tablet
Pms-Metoprolol-L 50 mg Tablet0.13USD tablet
Sandoz Metoprolol (Type L) 50 mg Tablet0.13USD tablet
Apo-Metoprolol 25 mg Tablet0.07USD tablet
Pms-Metoprolol-L 25 mg Tablet0.07USD tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
PatentsNot Available
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point120 °C (tartarate salt)Not Available
water solubility1.69E+004 mg/L (at 25 °C)MCFARLAND,JW ET AL. (2001)
logP1.88HANSCH,C ET AL. (1995)
Caco2 permeability-4.59ADME Research, USCD
Predicted Properties
PropertyValueSource
Water Solubility0.402 mg/mLALOGPS
logP1.8ALOGPS
logP1.76ChemAxon
logS-2.8ALOGPS
pKa (Strongest Acidic)14.09ChemAxon
pKa (Strongest Basic)9.67ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count4ChemAxon
Hydrogen Donor Count2ChemAxon
Polar Surface Area50.72 Å2ChemAxon
Rotatable Bond Count9ChemAxon
Refractivity76.7 m3·mol-1ChemAxon
Polarizability31.9 Å3ChemAxon
Number of Rings1ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
LC-MS/MSLC-MS/MS Spectrum - Quattro_QQQ 10V, N/A (Annotated)splash10-0v0c-3248359000-0353ef81c3bc6d7fcfd5View in MoNA
LC-MS/MSLC-MS/MS Spectrum - Quattro_QQQ 25V, N/A (Annotated)splash10-014l-2514911000-b5f7785723f1eaf61e6fView in MoNA
LC-MS/MSLC-MS/MS Spectrum - Quattro_QQQ 40V, N/A (Annotated)splash10-05ir-1729351100-fb362124379cb4616c5eView in MoNA
1D NMR1H NMR SpectrumNot Available
2D NMR[1H,13C] 2D NMR SpectrumNot Available
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as tyrosols and derivatives. These are compounds containing a hydroxyethyl group attached to the C4 carbon of a phenol group.
KingdomOrganic compounds
Super ClassBenzenoids
ClassBenzene and substituted derivatives
Sub ClassPhenols and derivatives
Direct ParentTyrosols and derivatives
Alternative Parents
Substituents
  • Tyrosol derivative
  • Phenol ether
  • Alkyl aryl ether
  • Secondary alcohol
  • 1,2-aminoalcohol
  • Secondary amine
  • Ether
  • Secondary aliphatic amine
  • Dialkyl ether
  • Hydrocarbon derivative
  • Organooxygen compound
  • Organonitrogen compound
  • Amine
  • Alcohol
  • Aromatic homomonocyclic compound
Molecular FrameworkAromatic homomonocyclic compounds
External DescriptorsNot Available

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
antagonist
General Function:
Receptor signaling protein activity
Specific Function:
Beta-adrenergic receptors mediate the catecholamine-induced activation of adenylate cyclase through the action of G proteins. This receptor binds epinephrine and norepinephrine with approximately equal affinity. Mediates Ras activation through G(s)-alpha- and cAMP-mediated signaling.
Gene Name:
ADRB1
Uniprot ID:
P08588
Molecular Weight:
51322.1 Da
References
  1. Schafer M, Frischkopf K, Taimor G, Piper HM, Schluter KD: Hypertrophic effect of selective beta(1)-adrenoceptor stimulation on ventricular cardiomyocytes from adult rat. Am J Physiol Cell Physiol. 2000 Aug;279(2):C495-503. [PubMed:10913016 ]
  2. Staudt A, Mobini R, Fu M, Grosse Y, Stangl V, Stangl K, Thiele A, Baumann G, Felix SB: beta(1)-Adrenoceptor antibodies induce positive inotropic response in isolated cardiomyocytes. Eur J Pharmacol. 2001 Jul 6;423(2-3):115-9. [PubMed:11448474 ]
  3. Staudt Y, Mobini R, Fu M, Felix SB, Kuhn JP, Staudt A: Beta1-adrenoceptor antibodies induce apoptosis in adult isolated cardiomyocytes. Eur J Pharmacol. 2003 Apr 11;466(1-2):1-6. [PubMed:12679135 ]
  4. Johnson JA, Zineh I, Puckett BJ, McGorray SP, Yarandi HN, Pauly DF: Beta 1-adrenergic receptor polymorphisms and antihypertensive response to metoprolol. Clin Pharmacol Ther. 2003 Jul;74(1):44-52. [PubMed:12844134 ]
  5. Liu J, Liu ZQ, Tan ZR, Chen XP, Wang LS, Zhou G, Zhou HH: Gly389Arg polymorphism of beta1-adrenergic receptor is associated with the cardiovascular response to metoprolol. Clin Pharmacol Ther. 2003 Oct;74(4):372-9. [PubMed:14534524 ]
  6. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
Protein homodimerization activity
Specific Function:
Beta-adrenergic receptors mediate the catecholamine-induced activation of adenylate cyclase through the action of G proteins. The beta-2-adrenergic receptor binds epinephrine with an approximately 30-fold greater affinity than it does norepinephrine.
Gene Name:
ADRB2
Uniprot ID:
P07550
Molecular Weight:
46458.32 Da
References
  1. Zebrack JS, Munger M, Macgregor J, Lombardi WL, Stoddard GP, Gilbert EM: Beta-receptor selectivity of carvedilol and metoprolol succinate in patients with heart failure (SELECT trial): a randomized dose-ranging trial. Pharmacotherapy. 2009 Aug;29(8):883-90. doi: 10.1592/phco.29.8.883. [PubMed:19637941 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitor
General Function:
Steroid hydroxylase activity
Specific Function:
Responsible for the metabolism of many drugs and environmental chemicals that it oxidizes. It is involved in the metabolism of drugs such as antiarrhythmics, adrenoceptor antagonists, and tricyclic antidepressants.
Gene Name:
CYP2D6
Uniprot ID:
P10635
Molecular Weight:
55768.94 Da
References
  1. Belpaire FM, Wijnant P, Temmerman A, Rasmussen BB, Brosen K: The oxidative metabolism of metoprolol in human liver microsomes: inhibition by the selective serotonin reuptake inhibitors. Eur J Clin Pharmacol. 1998 May;54(3):261-4. [PubMed:9681670 ]
  2. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
  3. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Steroid hydroxylase activity
Specific Function:
Responsible for the metabolism of a number of therapeutic agents such as the anticonvulsant drug S-mephenytoin, omeprazole, proguanil, certain barbiturates, diazepam, propranolol, citalopram and imipramine.
Gene Name:
CYP2C19
Uniprot ID:
P33261
Molecular Weight:
55930.545 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]

Transporters

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Quaternary ammonium group transmembrane transporter activity
Specific Function:
Mediates tubular uptake of organic compounds from circulation. Mediates the influx of agmatine, dopamine, noradrenaline (norepinephrine), serotonin, choline, famotidine, ranitidine, histamin, creatinine, amantadine, memantine, acriflavine, 4-[4-(dimethylamino)-styryl]-N-methylpyridinium ASP, amiloride, metformin, N-1-methylnicotinamide (NMN), tetraethylammonium (TEA), 1-methyl-4-phenylpyridiniu...
Gene Name:
SLC22A2
Uniprot ID:
O15244
Molecular Weight:
62579.99 Da
References
  1. Dudley AJ, Bleasby K, Brown CD: The organic cation transporter OCT2 mediates the uptake of beta-adrenoceptor antagonists across the apical membrane of renal LLC-PK(1) cell monolayers. Br J Pharmacol. 2000 Sep;131(1):71-9. [PubMed:10960071 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitor
General Function:
Xenobiotic-transporting atpase activity
Specific Function:
Energy-dependent efflux pump responsible for decreased drug accumulation in multidrug-resistant cells.
Gene Name:
ABCB1
Uniprot ID:
P08183
Molecular Weight:
141477.255 Da
References
  1. Takara K, Kakumoto M, Tanigawara Y, Funakoshi J, Sakaeda T, Okumura K: Interaction of digoxin with antihypertensive drugs via MDR1. Life Sci. 2002 Feb 15;70(13):1491-500. [PubMed:11895100 ]
  2. Doppenschmitt S, Langguth P, Regardh CG, Andersson TB, Hilgendorf C, Spahn-Langguth H: Characterization of binding properties to human P-glycoprotein: development of a [3H]verapamil radioligand-binding assay. J Pharmacol Exp Ther. 1999 Jan;288(1):348-57. [PubMed:9862789 ]
  3. Neuhoff S, Ungell AL, Zamora I, Artursson P: pH-dependent bidirectional transport of weakly basic drugs across Caco-2 monolayers: implications for drug-drug interactions. Pharm Res. 2003 Aug;20(8):1141-8. [PubMed:12948010 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on August 17, 2016 12:23